WO2023187130A1 - Activatable bispecific anti-cd3 and anti-pd-l1 proteins and uses thereof - Google Patents

Activatable bispecific anti-cd3 and anti-pd-l1 proteins and uses thereof Download PDF

Info

Publication number
WO2023187130A1
WO2023187130A1 PCT/EP2023/058418 EP2023058418W WO2023187130A1 WO 2023187130 A1 WO2023187130 A1 WO 2023187130A1 EP 2023058418 W EP2023058418 W EP 2023058418W WO 2023187130 A1 WO2023187130 A1 WO 2023187130A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
seq
acid sequence
cancer
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2023/058418
Other languages
English (en)
French (fr)
Inventor
William James Jonathan Finlay
Kristina GEGENBAUER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lockbody Therapeutics Ltd
Original Assignee
Lockbody Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020247035680A priority Critical patent/KR20240163741A/ko
Priority to JP2024557583A priority patent/JP2025511002A/ja
Priority to IL315768A priority patent/IL315768A/en
Priority to CA3246893A priority patent/CA3246893A1/en
Priority to AU2023246985A priority patent/AU2023246985A1/en
Priority to EP23717433.9A priority patent/EP4499232A1/en
Application filed by Lockbody Therapeutics Ltd filed Critical Lockbody Therapeutics Ltd
Priority to CN202380038600.4A priority patent/CN119677780A/zh
Publication of WO2023187130A1 publication Critical patent/WO2023187130A1/en
Priority to US18/889,571 priority patent/US20250109206A1/en
Priority to MX2024011776A priority patent/MX2024011776A/es
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Definitions

  • the disclosure relates to activatable bispecific proteins and treatments for cancer.
  • PD-L1 is a cell surface receptor that is a member of the immunoglobulin superfamily and is principally expressed on myeloid cells and regulatory T (Treg) cells in non-diseased tissues.
  • Treg regulatory T
  • PD-L1 has also been observed to be highly expressed on some cancer cells.
  • PD-L1 binds to the membrane protein PD1.
  • the interaction of PD-L1 with PD1 on T cells down-regulates T cell inflammatory activity, which promotes immune self-tolerance.
  • PD-L1 is, therefore, described as an immune checkpoint.
  • PD-L1 is a drug target used to amplify the adaptive immune system’s anti-cancer effects.
  • tumors may use multiple ‘escape mechanisms’ to negate the effects of PD-L1 agents, such as the downregulation of MHC class 1 and downregulation of cancer neoantigen expression.
  • CD3 cluster of differentiation 3
  • CD3e Cluster of differentiation 3
  • CD3e Cluster of differentiation 3
  • CD3e chain which, upon binding, can induce a TCR activation signal in T lymphocytes which may lead to increased cytolytic activity against infected or cancerous cells.
  • CD3- ligating bispecific agents have also been generated that may direct T cell killing activity to target-specific cell classes without the need for TCR recognition of MHC-presented antigens on the target cells.
  • Anti-PD-Ll antibodies could therefore be made more potent and broadly-acting therapeutic agents by gaining the ability to also bind CD3e and thereby strongly engage T cell killing mechanisms in PD-L1 antibody -resistant disease settings. This would combine a key checkpoint inhibitor function with an inducible “synthetic immunity” that can synergistically stimulate the adaptive immune system.
  • the ability to make this combination work in a single therapeutic agent structure e.g., in standard bispecific antibody format with fully active PD-L1 and CD3 binding domains
  • the ability to make this combination work in a single therapeutic agent structure is limited by the relatively broad expression profiles of both PD-L1 and CD3 on many cell types such as T cells and myeloid cells, as well as others.
  • a protein comprising a first polypeptide chain comprising a heavy chain and a second polypeptide chain comprising a light chain
  • the heavy chain comprises, in N-terminus to C-terminus order, an anti-PD-Ll heavy chain variable (VH) domain, a first CHI domain, a first linker, an anti-CD3 VH domain, and a second CHI domain
  • the light chain comprises, in N-terminus to C- terminus order, an anti-PD-Ll light chain variable (VL) domain, a first immunoglobulin light chain constant region, a second linker, an anti-CD3 VL domain, and a second immunoglobulin light chain constant region.
  • a protein comprising a first polypeptide chain comprising a heavy chain and a second polypeptide chain comprising a light chain
  • the heavy chain comprises, in N-terminus to C-terminus order, an anti-PD-Ll heavy chain variable (VH) domain, a first CHI domain, a first linker, an anti-CD3 light chain variable (VL) domain, and a first immunoglobulin light chain constant region
  • the light chain comprises, in N-terminus to C-terminus order, anti-PD-Ll VL domain, a second immunoglobulin light chain constant region, a second linker, an anti- CD3 VH domain, and a second CHI domain.
  • the heavy chain comprises in N-terminus to C-terminus order, the anti-PD-Ll VH domain, the first CHI domain, the first linker, the anti-CD3 VH domain, the second CHI domain, a hinge, a CH2 domain, and a CH3 domain.
  • the protein further comprises a third polypeptide chain comprising a hinge, a CH2 domain, and a CH3 domain.
  • the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 124.
  • a protein provided herein further comprises a moiety that provides half-life extension.
  • the moiety that provides half-life extension is polyethylene glycol (PEG) or an albumin binding domain.
  • a protein comprising a first polypeptide chain comprising a heavy chain and a second polypeptide chain comprising a light chain
  • the heavy chain comprises, in N-terminus to C-terminus order, an anti-PD-Ll heavy chain variable (VH) domain, a first CHI domain, a first linker, an anti-CD3 VH domain, a second CHI domain, a first hinge, a first CH2 domain, and a first CH3 domain
  • the light chain comprises, in N-terminus to C-terminus order, an anti-PD-Ll light chain variable (VL) domain, a first immunoglobulin light chain constant region, a second linker, an anti-CD3 VL domain, a second immunoglobulin light chain constant region, a second hinge, a second CH2 domain, and a second CH3 domain.
  • the first linker comprises the amino acid sequence of any one of SEQ ID NOs: 1-12.
  • the second linker comprises the amino acid sequence of any one of SEQ ID NOs: 1-12.
  • the anti-PD-Ll VH domain comprises a HCDR1 comprising the amino acid sequence of SEQ ID NO: 20, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 21, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 22; and the anti-PD-Ll VL domain comprises a LCDR1 comprising the amino acid sequence of SEQ ID NO: 23, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 24, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 25.
  • the anti-CD3 VH domain comprises a HCDR1 comprising the amino acid sequence of SEQ ID NO: 26, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 27, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 29; and the anti-CD3 VL domain comprises a LCDR1 comprising the amino acid sequence of SEQ ID NO: 30, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 31, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 32.
  • the anti-CD3 VH domain comprises a HCDR1 comprising the amino acid sequence of SEQ ID NO: 26, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 28, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 29; and the anti-CD3 VL domain comprises a LCDR1 comprising the amino acid sequence of SEQ ID NO: 30, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 31, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 32.
  • the anti-PD-Ll VH domain comprises a HCDR1 comprising the amino acid sequence of SEQ ID NO: 20, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 21, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 22;
  • the anti-PD-Ll VL domain comprises a LCDR1 comprising the amino acid sequence of SEQ ID NO: 23, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 24, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 25;
  • the anti-CD3 VH domain comprises aHCDRl comprising the amino acid sequence of SEQ ID NO: 26, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 27, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 29; and
  • the anti-CD3 VL domain comprises a LCDR1 comprising the amino acid sequence of SEQ ID NO: 30, a LCDR2 comprising the amino acid sequence of SEQ
  • the anti-PD-Ll VH domain comprises a HCDR1 comprising the amino acid sequence of SEQ ID NO: 20, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 21, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 22;
  • the anti-PD-Ll VL domain comprises a LCDR1 comprising the amino acid sequence of SEQ ID NO: 23, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 24, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 25;
  • the anti-CD3 VH domain comprises aHCDRl comprising the amino acid sequence of SEQ ID NO: 26, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 28, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 29; and
  • the anti-CD3 VL domain comprises a LCDR1 comprising the amino acid sequence of SEQ ID NO: 30, a LCDR2 comprising the amino acid sequence of SEQ
  • the anti-PD-Ll VH domain comprises the amino acid sequence of any one of SEQ ID NOs: 33 and 54-107. In some embodiments, the anti- PD-Ll VL domain comprises the amino acid sequence of SEQ ID NO: 34.
  • the anti-PD-Ll VH domain comprises the amino acid sequence of any one of SEQ ID NOs: 33 and 54-107, and the anti-PD-Ll VL domain comprises the amino acid sequence of SEQ ID NO: 34.
  • the anti-CD3 VH domain comprises the amino acid sequence of any one of SEQ ID NOs: 44-48. In some embodiments, the anti-CD3 VL domain comprises the amino acid sequence of any one of SEQ ID NOs: 37-42.
  • the heavy chain comprises the amino acid sequence of any one of SEQ ID NOs: 116-123, 129-132, 137-141, 142, 144, 146, 147, 148, 150, and 152.
  • the light chain comprises the amino acid sequence of any one of SEQ ID NOs: 53, 108-115, 125-128, and 133-136, 143, 145, 151, and 153.
  • the heavy chain comprises the amino acid sequence of SEQ ID NO: 122
  • the light chain comprises the amino acid sequence of SEQ ID NO: 114
  • the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 124;
  • the heavy chain comprises the amino acid sequence of SEQ ID NO: 123
  • the light chain comprises the amino acid sequence of SEQ ID NO: 115
  • the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 124;
  • the heavy chain comprises the amino acid sequence of SEQ ID NO: 116
  • the light chain comprises the amino acid sequence of SEQ ID NO: 108
  • the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 124;
  • the heavy chain comprises the amino acid sequence of SEQ ID NO: 117
  • the light chain comprises the amino acid sequence of SEQ ID NO: 109
  • the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 124;
  • the heavy chain comprises the amino acid sequence of SEQ ID NO: 118
  • the light chain comprises the amino acid sequence of SEQ ID NO: 108
  • the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 124;
  • the heavy chain comprises the amino acid sequence of SEQ ID NO: 119
  • the light chain comprises the amino acid sequence of SEQ ID NO: 109
  • the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 124;
  • the heavy chain comprises the amino acid sequence of SEQ ID NO: 120
  • the light chain comprises the amino acid sequence of SEQ ID NO: 108
  • the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 124;
  • the heavy chain comprises the amino acid sequence of SEQ ID NO: 116
  • the light chain comprises the amino acid sequence of SEQ ID NO: 110
  • the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 124;
  • the heavy chain comprises the amino acid sequence of SEQ ID NO: 118
  • the light chain comprises the amino acid sequence of SEQ ID NO: 110
  • the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 124;
  • the heavy chain comprises the amino acid sequence of SEQ ID NO: 120, the light chain comprises the amino acid sequence of SEQ ID NO: 110, and the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 124;
  • the heavy chain comprises the amino acid sequence of SEQ ID NO: 116, the light chain comprises the amino acid sequence of SEQ ID NO: 111, and the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 124;
  • the heavy chain comprises the amino acid sequence of SEQ ID NO: 118
  • the light chain comprises the amino acid sequence of SEQ ID NO: 111
  • the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 124;
  • the heavy chain comprises the amino acid sequence of SEQ ID NO: 120
  • the light chain comprises the amino acid sequence of SEQ ID NO: 111
  • the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 124;
  • the heavy chain comprises the amino acid sequence of SEQ ID NO: 116
  • the light chain comprises the amino acid sequence of SEQ ID NO: 112
  • the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 124;
  • the heavy chain comprises the amino acid sequence of SEQ ID NO: 116
  • the light chain comprises the amino acid sequence of SEQ ID NO: 113
  • the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 124;
  • the heavy chain comprises the amino acid sequence of SEQ ID NO: 121
  • the light chain comprises the amino acid sequence of SEQ ID NO: 108
  • the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 124;
  • the heavy chain comprises the amino acid sequence of SEQ ID NO: 131
  • the light chain comprises the amino acid sequence of SEQ ID NO: 127
  • the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 124;
  • the heavy chain comprises the amino acid sequence of SEQ ID NO: 120
  • the light chain comprises the amino acid sequence of SEQ ID NO: 127
  • the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 124.
  • the heavy chain comprises an IgG, IgE, IgM, IgD, IgA, or IgY constant region. In some embodiments, the heavy chain comprises an IgGl, IgG2, IgG3, IgG4, IgAl or IgA2 constant region. In some embodiments, the heavy chain comprises an immunologically inert constant region.
  • the heavy chain comprises a wild-type human IgGl constant region, a human IgGl constant region comprising the amino acid substitutions L234A, L235A and G237A, a wild-type human IgG2 constant region, a wild-type human IgG4 constant region, or a human IgG4 constant region comprising the amino acid substitution S228P, wherein numbering is according to the EU index as in Kabat.
  • an immunoconjugate comprising a protein disclosed herein, linked to a therapeutic agent.
  • the therapeutic agent is a cytotoxin, a radioisotope, a chemotherapeutic agent, an immunomodulatory agent, a cytostatic enzyme, a cytolytic enzyme, a therapeutic nucleic acid, an anti-angiogenic agent, an anti-proliferative agent, or a pro-apoptotic agent.
  • composition comprising a protein or an immunoconjugate disclosed herein, and a pharmaceutically acceptable carrier.
  • nucleic acid molecule encoding (a) the first polypeptide chain amino acid sequence; (b) the second polypeptide chain amino acid sequence; or (c) both the first polypeptide chain and the second polypeptide chain amino acid sequences of a protein disclosed herein.
  • nucleic acid molecule encoding (a) the heavy chain amino acid sequence; (b) the light chain amino acid sequence; or (c) both the heavy chain and the light chain amino acid sequences of a protein disclosed herein.
  • an expression vector comprising a nucleic acid molecule disclosed herein.
  • a recombinant host cell comprising a nucleic acid molecule or an expression vector disclosed herein.
  • a method of producing a protein comprising: culturing a recombinant host cell disclosed herein under conditions whereby the nucleic acid molecule is expressed, thereby producing the protein; and isolating the protein from the host cell or culture.
  • a method for enhancing an anti-cancer immune response in a subject comprising administering to the subject a therapeutically effective amount of a protein, an immunoconjugate, or a pharmaceutical composition disclosed herein.
  • a method for treating cancer in a subject comprising administering to the subject a therapeutically effective amount of a protein, an immunoconjugate, or a pharmaceutical composition disclosed herein.
  • a method for ameliorating a symptom of cancer in a subject comprising administering to the subject a therapeutically effective amount of a protein, an immunoconjugate, or a pharmaceutical composition disclosed herein.
  • a protein, an immunoconjugate, or a pharmaceutical composition disclosed herein for use in enhancing an anti-cancer immune response in a subject.
  • a protein, an immunoconjugate, or a pharmaceutical composition disclosed herein for use in treating cancer in a subject.
  • the cancer is gastrointestinal stromal cancer (GIST), pancreatic cancer, skin cancer, melanoma, breast cancer, lung cancer, bronchial cancer, colorectal cancer, prostate cancer, stomach cancer, ovarian cancer, urinary bladder cancer, brain cancer, central nervous system cancer, peripheral nervous system cancer, esophageal cancer, cervical cancer, uterine cancer, endometrial cancer, cancer of the oral cavity or pharynx, liver cancer, kidney cancer, renal cell carcinoma, testicular cancer, biliary tract cancer, small bowel cancer, appendix cancer, salivary gland cancer, thyroid cancer, adrenal gland cancer, osteosarcoma, chondrosarcoma, or cancer of hematological tissues.
  • GIST gastrointestinal stromal cancer
  • pancreatic cancer skin cancer, melanoma, breast cancer, lung cancer, bronchial cancer, colorectal cancer, prostate cancer, stomach cancer, ovarian cancer, urinary bladder cancer, brain cancer, central nervous system cancer, peripheral nervous system cancer, esophageal cancer
  • FIG. 1A depicts a diagram of a protein molecule disclosed herein in intact (left), activated protease-cleaved (middle) and deactivated protease-cleaved (right) conformations.
  • the PD-L1 Fab binding domain is exposed and able to bind their cognate target.
  • the CD3 Fab domain is inhibited from binding by linkers in both the heavy and light chains that are both proteolytically cleavable and may be sequentially cleaved by matrix metalloproteases (MMPs) and/or cathepsins.
  • MMPs matrix metalloproteases
  • a first cleavage event creates an intermediate active state which allows both PD-L1 and CD3 Fabs from a single protein construct to bind their cognate targets, thereby potentially directing killing of PD-L1+ cells by directed activation of CD3+ T cells.
  • a second cleavage dissociates the PD-L1 and CD3 Fabs, removing the ability of a single molecule to bind both PD-L1 and CD3 simultaneously.
  • FIG. IB depicts a detailed diagram of an intact asymmetric LB (LockBody) protein consisting of heavy chain, light chain and Fc stump.
  • Each light chain is comprised of two Fabs linked by a lower hinge linker (LHL).
  • Each heavy chain is comprised of two Fabs linked by a lower hinge linker (LHL) an Fc hinge and Fc fragment containing both CH2 and CH3 domains with either N-linked glycosylation sites (CH2) or Knobs mutations (CH3).
  • the asymmetric LB protein contains a third polypeptide which contains both CH2 and CH3 domains with either N-linked glycosylation sites (CH2) or Holes mutations (CH3).
  • FIG. 1C depicts diagrams of alternative formats for the protein molecules disclosed herein, where the molecule may; lack an Fc fragment (left); may lack an Fc fragment but achieve half-life extension (HLE) through an alternative mechanism such as PEGylation, addition of an albumin binding domain, etc. (center); or may contain an Fc fragment but be constructed from only two polypeptides (right) as symmetric one- arm constructs.
  • Each polypeptide chain contains either two light chain Fabs linked by lower hinge linkers, an Fc hinge without disulfide bonds and Fc fragment (CH2 and CH3 domains) or two heavy chain Fabs linked by lower hinge linkers, an Fc hinge without disulfide bonds and Fc fragment (CH2 and CH3 domains).
  • FIG. ID depicts detailed diagrams of asymmetric one-arm constructs in which the two polypeptide chains contain one light chain and one heavy chain Fab linked by LHL. As above, each polypeptide chain further contains an Fc hinge without disulfide bonds and Fc fragment (CH2 and CH3 domains).
  • FIG. 2 depicts a diagram of one proposed mechanism of activity of activatable bispecific protein molecules provided herein.
  • FIG. 3A - FIG. 3G depict activity of (1) IgGl isotype, (2) a commercial CD3xHer2 Bispecific T cell Engager (BiTE) used as a positive control anti-Her2/anti- CD3 bispecific antibody as indicated or (3) test articles (before or after treatment with MMP12 for 0, 0.5 hour, 1 hour or 4 hours) in a cell-based assay that measures the ability of agents to bind hPD-Ll on MDA-MB231 cancer cells and induce CD3 signaling on co-cultured Jurkat cells (measured in fold activation).
  • BiTE CD3xHer2 Bispecific T cell Engager
  • FIG. 3A depicts activity of IgGl isotype, CD3xHer2 BiTE used as a positive control and test article LB204 (before or after treatment with MMP12 for 0 or 4 hours). LB204 induces low CD3 signal before MMP12 treatment and moderate CD3 fold activation after MMP12 treatment that stays below levels induced by the commercial CD3xHer2 BiTE control.
  • FIG. 3B depicts activity of IgGl isotype, CD3xHer2 BiTE used as a positive control and test article LB206 (before or after treatment with MMP12 for 0 or 4 hours). LB206 induces low CD3 signal before MMP12 treatment and high CD3 signal after treatment with MMP12 with higher levels compared to commercial CD3xHer2 BiTE control.
  • FIG. 3A depicts activity of IgGl isotype, CD3xHer2 BiTE used as a positive control and test article LB204 (before or after treatment with MMP12 for 0 or 4 hours). LB206 induces low CD3 signal before MMP
  • FIG. 3C depicts activity of IgGl isotype, CD3xHer2 BiTE used as a positive control and test article LB208 (before or after treatment with MMP12 for 0 or 4 hours). LB208 induces no CD3 signal before MMP12 treatment and moderate CD3 fold activation after MMP12 treatment that stays below levels induced by the commercial CD3xHer2 BiTE control.
  • FIG. 3D depicts activity of IgGl isotype, CD3xHer2 BiTE used as a positive control and test article LB209 (before or after treatment with MMP12 for 0 or 4 hours). LB209 induces no CD3 signal before MMP12 treatment and moderate CD3 fold activation after MMP12 treatment that stays below levels induced by the commercial CD3xHer2 BiTE control.
  • FIG. 3C depicts activity of IgGl isotype, CD3xHer2 BiTE used as a positive control and test article LB208 (before or after treatment with MMP12 for 0 or 4 hours). LB209 induces no
  • FIG. 3E depicts activity of IgGl isotype, CD3xHer2 BiTE used as a positive control and test article LB210 (before or after treatment with MMP12 for 0 or 4 hours). LB210 induces no CD3 signal before MMP12 treatment or after.
  • FIG. 3F depicts activity of IgGl isotype, CD3xHer2 BiTE used as a positive control and test article LB213 (before or after treatment with MMP12 for 0 or 4hours). LB213 induces no CD3 signal before MMP12 treatment and relatively high CD3 signal after treatment with MMP12 but staying below levels induced by the commercial CD3xHer2 BiTE control.
  • 3G depicts activity of IgGl isotype, test article LB205 (before or after treatment with MMP12 for 0, 0.5 or 1 hour). LB205 induces no CD3 signal before MMP12 treatment and high CD3 signal after treatment with MMP12 for either 0.5 hour or 1 hour.
  • FIG. 4A - FIG. 4D depict the characterization (SPR, ELISA, and Jurkat activity) of Fab and IgG formats of two CD3 humanization variants.
  • FIG. 4A depicts surface plasmon resonance (SPR) binding of each V domain humanization variant (in monovalent Fab format) to human recombinant CD3 ⁇ heterodimer.
  • FIG. 4B depicts surface plasmon resonance (SPR) binding of each V domain humanization variant (in monovalent Fab format) to cynomolgus (cyno) monkey recombinant CD3 ⁇ heterodimer.
  • SPR surface plasmon resonance
  • FIG. 4C shows IgG binding of IgGOOl and IgG002 to human and cyno recombinant CD3 ⁇ heterodimer in ELISA.
  • FIG. 4D depicts CD3 dependent activation assay comparing emitted luciferase signals from Jurkat reporter cells stimulated with SP34 IgG or its respective humanization variants in IgG format.
  • FIG. 5A depicts MMP12 digested LB proteins run on SDS PAGE under reducing or non-reducing conditions.
  • 2 ⁇ g/lane of exemplary LB proteins 204, 206, 208, 209, 210 and 213 previously incubated with MMP12 for Oh and 4h show differential digestion profiles.
  • a prominent 25kDa/50kDa band in reducing/non-reducing SDS-PAGE respectively, resulting from light chain cleavage and disappearing intact heavy chains at 75kDa in reducing conditions (and 150kDa in non-reducing conditions) can be observed in concert, demonstrating that linkers in both the heavy and light chains become cleaved.
  • FIG. 5B depicts MMP12 digested LB proteins run on SDS PAGE under reducing or non-reducing conditions.
  • 2pg/lane of LB proteins LB206 and LB220 previously incubated with MMP12 for Oh, 5 min, 15min, 30min, 60min or 120min show differential digestion profiles.
  • a prominent 25kDa/50kDa band in reducing/non-reducing SDS-PAGE respectively, resulting from light chain cleavage and disappearing intact heavy chains at 75kDa in reducing conditions (and 150kDa in non-reducing conditions) can be observed in concert, demonstrating that linkers in both the heavy and light chains become cleaved.
  • LB protein LB220 appears to be cleaved at a faster rate by MMP12 than LB206.
  • FIG. 6A - FIG. 6C depict activity of IgGl isotype or test articles (before or after treatment with MMP12 for 0, 0.5 or Ihours) in a cell-based assay which measures the ability of test agents to bind hPD-Ll on MDA-MB231 cancer cells and induce CD3 signaling on co-cultured Jurkat cells (measured in fold activation).
  • FIG. 6A depicts activity of IgGl isotype, test article LB217 (before or after treatment with MMP12 for 0, 0.5 or 1 hour). LB217 induces low CD3 signal before MMP12 treatment and high CD3 signal after treatment with MMP12 for either 0.5hour or Ih hour.
  • FIG. 6B depicts activity of IgGl isotype, test article LB218 (before or after treatment with MMP12 for 0, 0.5 or 1 hour).
  • LB217 induces no CD3 signal before MMP12 treatment and high CD3 signal after treatment with MMP12 for 0.5hour.
  • CD3 signal after treatment with MMP12 for Ih hour is lower.
  • FIG. 6C depicts activity of IgGl isotype, test article LB220 (before or after treatment with MMP12 for 0, 0.5 or 1 hour).
  • LB 220 induces low CD3 signal before MMP12 treatment and high CD3 signal after treatment with MMP12 for 0.5 hour.
  • CD3 signal after treatment with MMP12 for Ih hour is much lower, similar to no MMP12 treatment.
  • FIG. 7A - FIG. 7H depict ELISA binding of intact or up to Ih MMP12 incubated LB proteins to human PD-L1 with atezolizumab as positive control or human and cyno CD3 ⁇ heterodimer.
  • the negative control protein used is human IgGl isotype.
  • FIG. 7A depicts ELISA binding of intact or 5min MMP12 incubated LB206 protein to human PD-L1 with atezolizumab as positive control or IgGl isotype as negative control (no signal). Intact and MMP12 treated LB206 bind to PD-L1 to a similar level.
  • FIG. 7A depicts ELISA binding of intact or up to Ih MMP12 incubated LB proteins to human PD-L1 with atezolizumab as positive control or human and cyno CD3 ⁇ heterodimer.
  • the negative control protein used is human IgGl isotype.
  • FIG. 7A depicts
  • FIG. 7B depicts ELISA binding of intact or 5 min MMP12 incubated LB206 protein to human CD3 ⁇ heterodimer or IgGl isotype as negative control (no signal). Intact LB206 binds to human CD3 ⁇ heterodimer to very low level. In contrast, MMP12 treated LB206 binds strongly to human CD3 ⁇ heterodimer.
  • FIG. 7C depicts ELISA binding of intact or 5min, 15min, 30min or 60min MMP12 incubated LB218 protein to human PD-L1 with IgGl isotype as negative control (no signal). Intact and 5 or 15min MMP12 treated LB218 bind to PD-L1 to a similar level.
  • FIG. 7D depicts ELISA binding of intact or 5min, 15min, 30min or 60min MMP12 incubated LB218 protein to human CD3 ⁇ heterodimer with IgGl isotype as negative control (no signal).
  • Intact LB218 shows binding to human CD3 ⁇ heterodimer to very low level. With increasing MMP12 treatment times, higher binding to human CD3 ⁇ heterodimer can be observed. 60min MMP12 treated LB218 shows highest binding to human CD3 ⁇ heterodimer.
  • FIG. 7E depicts ELISA binding of intact or 5 min, 15min, 30min or 60min MMP12 incubated LB218 protein to cyno CD3 ⁇ heterodimer with IgGl isotype as negative control (no signal).
  • Intact LB218 shows binding to cyno CD3 ⁇ heterodimer to very low level. With increasing MMP12 treatment times, higher binding to cyno CD3 ⁇ heterodimer can be observed. 60min MMP12 treated LB218 shows highest binding to cyno CD3 ⁇ heterodimer.
  • FIG. 7F depicts ELISA binding of intact or 5min, 15min, 30min or 60min MMP12 incubated LB213 protein to human PD-L1 with IgGl isotype as negative control (no signal). Intact and 5 or 15min MMP12 treated LB213 bind to PD-L1 to a similar level. While binding to PD-L1 appears lower for 30min and 60min, suggesting occurrence of protein cleavage 2 (FIG 1 A).
  • FIG. 7G depicts ELISA binding of intact or 5 min, 15min, 30min or 60min MMP12 incubated LB213 protein to human CD3 ⁇ heterodimer with IgGl isotype as negative control (no signal).
  • Intact LB213 shows binding to human CD3 ⁇ heterodimer to very low level. With increasing MMP 12 treatment times, higher binding to human CD3 ⁇ heterodimer can be observed. 60min MMP12 treated LB213 shows highest binding to human CD3 ⁇ heterodimer.
  • FIG. 7H depicts ELISA binding of intact or 5 min, 15min, 30min or 60min MMP12 incubated LB213 protein to cyno CD3 ⁇ heterodimer with IgGl isotype as negative control (no signal). Intact LB213 shows binding to cyno CD3 ⁇ heterodimer to very low level. With increasing MMP 12 treatment times, higher binding to cyno CD3 ⁇ heterodimer can be observed. 60min MMP12 treated LB213 shows highest binding to cyno CD3 ⁇ heterodimer.
  • FIG. 8A depicts Jurkat cell binding of intact or 0 to 2h MMP12 incubated LB protein LB206. No binding to Jurkat cells can be observed for intact LB206 (Omin) or isotype control. In contrast, all MMP12 treated samples show similar binding levels to Jurkat cells.
  • FIG. 8B depicts PDL-1 expression on three different cell lines after IFNy stimulation- A549, MDA-MB-231 and RKO cells.
  • FIG. 9A - FIG. 9F depict primary T cell killing of cancer cell lines (A549, RKO, MDA-MB-231) mediated by intact or MMP12 incubated LB proteins with indicated concentrations as measured by the Incucyte® live cell analysis platform.
  • FIG. 9A depicts primary T cell killing of cancer cell line A549 mediated by intact or 30min MMP12 incubated LB 206 as measured by the Incucyte® live cell analysis platform.
  • FIG. 9B depicts primary T cell killing of cancer cell line A549 mediated by intact or 30min MMP12 incubated LB 218 as measured by the Incucyte® live cell analysis platform.
  • FIG. 9A - FIG. 9F depict primary T cell killing of cancer cell lines (A549, RKO, MDA-MB-231) mediated by intact or MMP12 incubated LB proteins with indicated concentrations as measured by the Incucyte® live cell analysis platform.
  • FIG. 9A depicts primary T cell killing
  • FIG. 9C depicts primary T cell killing of cancer cell line RKO mediated by intact or 3 Omin MMP12 incubated LB 206 as measured by the Incucyte® live cell analysis platform.
  • FIG. 9D depicts primary T cell killing of cancer cell line RKO mediated by intact or 30min MMP12 incubated LB 218 as measured by the Incucyte® live cell analysis platform.
  • FIG. 9E depicts primary T cell killing of cancer cell line MDA-MB-231 mediated by intact or 30min MMP12 incubated LB 206 as measured by the Incucyte® live cell analysis platform.
  • FIG. 9F depicts primary T cell killing of cancer cell line MDA-MB-231 mediated by intact or 3 Omin MMP12 incubated LB 213 as measured by the Incucyte® live cell analysis platform.
  • FIG. 10A - FIG. 10E depict changes in tumor volume by caliper measurements (baseline corrected) or body weight changes in CD34+ myeloid boosted NCG mice with established MDA-MB-231 tumors over time while being treated with LB206, LB213, LB220, Atezolizumab or IgG isotype control.
  • FIG. 10A shows tumor volume by caliper measurements over time of LB206, IgG isotype control or Atezolizumab treated CD34+ myeloid boosted NCG mice with established MDA-MB-231 tumors. All LB206 treated groups (4.5mg/kg, 8.5mg/kg, 12mg/kg) show tumor regressions to a similar extent.
  • FIG. 10A shows tumor volume by caliper measurements over time of LB206, IgG isotype control or Atezolizumab treated CD34+ myeloid boosted NCG mice with established MDA-MB-231 tumors. All LB206 treated groups (4.5mg/kg, 8.5mg
  • FIG. 10B shows tumor volume by caliper measurements over time of LB220, IgG isotype control or Atezolizumab treated CD34+ myeloid boosted NCG mice with established MDA-MB-231 tumors. All LB220 treated groups (8.5mg/kg, 12mg/kg) show tumor regressions initially followed by tumor growth inhibition.
  • FIG. 10C shows tumor volume by caliper measurements over time of LB213, IgG isotype control or Atezolizumab treated CD34+ myeloid boosted NCG mice with established MDA-MB-231 tumors. All LB213 treated groups show dose dependent tumor growth inhibition (4.5, 8.5mg/kg, 12mg/kg).
  • FIG. 10D shows tumor volumes of individual tumors of either IgG isotype or LB206 treated CD34+ myeloid boosted NCG mice until Day 51. Dosing regimen is indicated by triangles. 5 out of 8 LB206 treated tumors remain regressed 33 days after treatment is stopped.
  • FIG. 10E shows mean body weight changes of all treatment groups over time. No group showed body weight loss beyond 10% at any time.
  • CD3-positive cells are found in the bloodstream and at high concentration in secondary lymphoid tissues, creating a large sink effect for this arm, affecting biodistribution and free drug availability for tumor penetration.
  • the anti-PD-Ll and anti-CD3 proteins overcome the peripheral sink and toxicity issues by minimizing binding of CD3 outside of diseased tissue. This effect is achieved by adding PD-L1 binding domains and linkers above (i. e. , amino-terminal to) the CD3 binding domains. The use of appropriate upper domain and linker combinations results in a configuration that minimizes binding activity in the lower (i.e., carboxy -terminal) CD3 domain. The PD-L1 domain then drives high concentration in PD-L1 enriched tumor microenvironments.
  • the protein construct linker system exploits the elevated MMP and cathepsin activity that is common in solid tumors to cleave the linker peptides, exposing the CD3 binding domains and thereby conditionally activating the CD3 -activating activity in the tumor, rather than the periphery. These combined biological functions thereby afford the molecule the potential to avoid the peripheral CD3 sink and maximize T cell immune responses to cancer cells, as outlined in FIG. 2.
  • proteins that are conditionally active in diseased human tissues.
  • the proteins of the disclosure are fully active in specifically binding and blocking PD-L1 throughout the body; exhibit minimized binding of CD3 in healthy tissue; and become highly activated in CD3 binding and activation once in the PD-L1- positive diseased tissue environment.
  • a protein of the disclosure comprises a CD3 binding domain that is masked by a PD-L1 binding domain in non-diseased tissues.
  • the protein also comprises two peptide linkers that are cleaved by one or more proteases expressed in a diseased tissue (e.g, a tumor). The linker cleavage unmasks the CD3 binding domain in the diseased tissue, thus allowing binding and/or function of the protein selectively in the diseased tissue.
  • proteins comprising two Fab fragments (an anti-PD-Ll Fab and an anti-CD3 Fab).
  • the protein is monovalent when in the intact structure and can only have a maximum of monovalent CD3 binding when activated, to minimize peripheral toxicity risk associated with bivalent, activating anti-CD3 antibodies.
  • a protein comprises a first polypeptide chain comprising a heavy chain and a second polypeptide chain comprising a light chain
  • the heavy chain comprises, in N-terminus to C-terminus order, an anti-PD-Ll heavy chain variable (VH) domain, a first CHI domain, a first linker, an anti-CD3 VH domain, and a second CHI domain
  • the light chain comprises, in N-terminus to C-terminus order, an anti-PD-Ll light chain variable (VL) domain, a first immunoglobulin light chain constant region, a second linker, an anti-CD3 VL domain, and a second immunoglobulin light chain constant region.
  • the heavy chain further comprises an immunoglobulin hinge region and an Fc domain at its C-terminus.
  • the heavy chain comprises in N-terminus to C-terminus order, the anti-PD-Ll VH domain, the first CHI domain, the first linker, the anti-CD3 VH domain, the second CHI domain, a hinge, a CH2 domain, and a CH3 domain.
  • the protein further comprises a third polypeptide chain comprising a hinge, a CH2 domain, and a CH3 domain.
  • the third polypeptide chain may be referred to as a “Fc-stump”.
  • FIG. 1A depicts a diagram of a protein molecule disclosed herein in intact (left), activated protease-cleaved (middle) and deactivated protease-cleaved (right) conformations.
  • the PD-L1 Fab binding domain is exposed and able to bind their cognate target.
  • the CD3 Fab domain is inhibited from binding by linkers in both the heavy and light chains that are both proteolytically cleavable and may be sequentially cleaved by matrix metalloproteases (MMPs) and/or cathepsins.
  • MMPs matrix metalloproteases
  • a first cleavage event creates an intermediate active state which allows both PD-L1 and CD3 Fabs from a single protein construct to bind their cognate targets, thereby potentially directing killing of PD-L1+ cells by directed activation of CD3+ T cells.
  • a second cleavage dissociates the PD-L1 and CD3 Fabs, removing the ability of a single molecule to bind both PD-L1 and CD3 simultaneously.
  • FIG. IB depicts a detailed diagram of an intact asymmetric LB (LockBody) protein consisting of heavy chain, light chain and Fc Stump. Each light chain is comprised of two Fabs linked by a lower hinge linker (LHL).
  • Each heavy chain is comprised of two Fabs linked by a lower hinge linker (LHL) an Fc hinge and Fc fragment containing both CH2 and CH3 domains with either N-linked glycosylation sites (CH2) or Knobs mutations (CH3).
  • LHL lower hinge linker
  • Fc hinge and Fc fragment containing both CH2 and CH3 domains with either N-linked glycosylation sites (CH2) or Knobs mutations (CH3).
  • the asymmetric LB protein contains a third polypeptide which contains both CH2 and CH3 domains with either N-linked glycosylation sites (CH2) or Holes mutations (CH3).
  • FIG. 1C depicts diagrams of alternative formats for the protein molecules disclosed herein, where the molecule may; lack an Fc fragment (left); may lack an Fc Fragment but achieve half-life extension (HLE) through an alternative mechanism such as PEGylation, addition of an albumin binding domain, etc.
  • FIG. ID depicts detailed diagrams of asymmetric one-arm constructs in which the two polypeptide chains contain one light chain and one heavy chain Fab linked by LHL. As above, each polypeptide chain further contains an Fc hinge without disulfide bonds and Fc fragment (CH2 and CH3 domains).
  • the first linker and the second linker are cleavable by matrix metalloproteases (MMPs) and/or cathepsins found in diseased tissues, such as tumors.
  • MMPs matrix metalloproteases
  • the linkers in the protein are immunoglobulin-derived hinge sequences that are both proteolytically sensitive and may be sequentially cleaved, with a first cleavage taking the intact structure and creating an intermediate active state which allows an anti-PD-Ll Fab and an anti-CD3 Fab from a single protein construct to bind their cognate targets.
  • a second cleavage event in the second linker removes the covalent linkage between the anti-PD- Ll Fab and the anti-CD3 Fab, abrogating the ability of the molecule to recruit T cell killing of PD-L1+ cells.
  • This secondary cleavage event thereby constitutes a “self- destruct mechanism” that minimizes risk of activated molecule escaping the tumor microenvironment.
  • Cleaved linkers based on immunoglobulin hinge sequences may also recruit increased immune effector function (antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and antibodydependent cellular phagocytosis (ADCP)) at the cell membrane via endogenous antihinge antibodies, which are a known phenomenon in human patients with (and even without) underlying autoreactive disease.
  • ADCC antibody-dependent cellular cytotoxicity
  • CDC complement-dependent cytotoxicity
  • ADCP antibodydependent cellular phagocytosis
  • a protein comprises one or more amino acid sequences provided in Table 1, Table 2, Table 6, Table 7, or Table 8.
  • the CDR sequences are underlined.
  • Table 3 describes selected Fab proteins generated with selected sequences from Table 2 as described. Both anti-CD3 Fab proteins were characterized further in SPR binding experiments as described in FIG. 4A. Table 3: Chain sequence combinations of illustrative anti-CD3 Fab sequences
  • Table 4 describes selected IgG proteins generated with selected sequences from Table 2 as described. Both CD3 IgG proteins were characterized further in ELISA binding experiments and Jurkat reporter assay as described in FIG. 4B and FIG. 4C.
  • Table 5 describes anti-PD-Ll VH variants. Individual point mutations of CDRs are generated by in silico modelling and summarized in Table 5. The aim of these anti- PD-Ll variants was affinity modification to cynomolgus and/or human PD-L1.
  • X 5 I, K, W, L, Y, Q, R
  • X 7 K, I, F, M, D, Y, L, W, H, R
  • Xn S, W, R, L, Q, G, Y, D, N, A, M
  • Table 6 depicts selected anti-PD-Ll VH variants heavy domains based on Table 5. The aim of these anti-PD-Ll variants was affinity maturation to cynomolgus and/or human PD-L1. Expression of each of the VH variable domains with wild-type (WT) VL variable domains in Fab format was carried out as well as subsequent determination of KD to human and cynomolgus PD-L1 in SPR.
  • WT wild-type
  • Table 6 Selected anti-PD-Ll VH variants based on VH CDR mutations outlined in Table 5.
  • Table 7 depicts illustrative full-length LB protein light and heavy chain sequences.
  • Each chain contains WT anti-PD-Ll variable domains followed by LHL and CD3 Fab variant.
  • heavy chains, Fc hinge and relevant Fc fragments are present as described in FIG. 1A and FIG. IB (right).
  • each chain contains WT anti-PD-Ll variable domains followed by LHL and CD3 Fab variant.
  • both light and heavy chain sequences are followed by Fc hinge and Fc fragment as illustrated in FIG. 1C.
  • Each polypeptide chain in Table 7 is named with: first, a number from 1 - 7 referencing the respective CD3 humanization chain used (Table 2); second, by either HH or LL or B-HH or B-LL referring to asymmetric or symmetric constructs (B-); and third, an optional letter or letters from X, F, R-F or RX- F, which denote details on the LHL sequence as specified in Table 1. Finally, an addition of HLE in this table refers to the option of adding an appropriate half-life extension moiety.
  • Table 7 Illustrative full-length light chain (LL) sequences and heavy (HH) chain sequences
  • Table 8 depicts illustrative full-length LB protein sequences as described in FIG. ID.
  • Each chain contains, in N-terminus to C-terminus order, WT anti-PD-Ll variable domains followed by LHL and CD3 Fab variant, Fc linker and Fc fragment.
  • each chain contains heavy and light variable domains as outlined and illustrated in FIG. ID.
  • Table 8 Illustrative full-length sequences with either heavy chains-light chain or light chain-heavy chain combinations
  • the anti-PD-Ll/anti-CD3 protein design may be based on sequences derived from IgGl, IgG2, IgG3, IgG4, IgE, IgM, or IgA and may or may not have effector function capacity.
  • a protein disclosed herein comprises an Fc fragment. In some embodiments, a protein disclosed herein does not comprise an Fc fragment. [0072] In some embodiments, a protein disclosed herein is fused or conjugated to a moiety that provides half-life extension (“HLE”). HLE may be achieved via PEGylation or through an alternative mechanism, such as (but not limited to) addition of an albumin binding domain. In some embodiments, a protein disclosed herein does not comprise an Fc fragment but is fused or conjugated to a moiety that provides HLE. In some embodiments, the moiety that provides HLE is fused to the heavy chain. In some embodiments, the moiety that provides HLE is fused to the light chain.
  • HLE half-life extension
  • Proteins disclosed herein comprise domains and regions of antibody molecules.
  • antibody broadly refers to an immunoglobulin (Ig) molecule, generally, comprising four polypeptide chains, two heavy (H) chains and two light (L) chains, or any functional fragment, mutant, variant, or derivative thereof, that retains the essential target binding features of an Ig molecule.
  • Ig immunoglobulin
  • Such mutant, variant, or derivative antibody formats are known in the art.
  • each heavy chain comprises a heavy chain variable domain (abbreviated herein as VH domain) and a heavy chain constant region.
  • the heavy chain constant region comprises three domains, CHI, CH2 and CH3.
  • IgG, IgA, and IgD constant regions comprise a flexible hinge region between the CHI domain and the CH2 domain.
  • Each light chain comprises a light chain variable domain (abbreviated herein as VL domain) and a light chain constant region.
  • the light chain constant region comprises one domain, CL.
  • the VH and VL domains can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDRs), interspersed with regions that are more conserved, termed framework regions (FRs).
  • CDRs complementarity determining regions
  • FRs framework regions
  • Each VH domain and VL domain is composed of three CDRs and four FRs, arranged from amino-terminus to carboxyl-terminus in the following order: FR1, CDR1, FR2, C
  • the term “Fc region” is used to define a C-terminal region of an immunoglobulin heavy chain.
  • the “Fc region” may be a native sequence Fc region or a variant Fc region.
  • the human IgG heavy chain Fc region is usually defined to stretch from an amino acid residue at position Cys226, or from Pro230, to the carboxyl- terminus thereof.
  • the numbering of the residues in the Fc region is according to the EU index as in Kabat.
  • the Fc region of an immunoglobulin generally comprises two constant domains, CH2 and CH3.
  • An Fc region can be present in dimer or monomeric form.
  • the Fc region binds to various cell receptors, such as Fc receptors, and other immune molecules, such as complement proteins.
  • a protein provided herein comprises two Fab fragments.
  • a Fab fragment is a monovalent antigen-binding fragment consisting of the VL, VH, CL and CHI domains.
  • Immunoglobulin molecules can be of any type (e.g., IgG, IgE, IgM, IgD, IgA or IgY) and class (e.g., IgGl, IgG2, IgG3, IgG4, IgAl or IgA2) or subclass.
  • IgG, IgD, and IgE antibodies generally contain two identical heavy chains and two identical light chains and two antigen combining domains, each composed of a VH) and a VL.
  • IgA antibodies are composed of two monomers, each monomer composed of two heavy chains and two light chains (as for IgG, IgD, and IgE antibodies); in this way the IgA molecule has four antigen binding domains, each again composed of a VH and a VL.
  • Certain IgA antibodies are monomeric in that they are composed of two heavy chains and two light chains.
  • Secreted IgM antibodies are generally composed of five monomers, each monomer composed of two heavy chains and two light chains (as for IgG and IgE antibodies).
  • the IgM molecule has ten antigen binding domains, each again composed of a VH and a VL.
  • a cell surface form of IgM has a two heavy chain/two light chain structure similar to IgG, IgD and IgE antibodies.
  • immunological binding and “immunological binding properties” refer to the non-covalent interactions of the type which occur between an immunoglobulin molecule (e.g., antibody or antigen-binding portion thereof), or a protein comprising an immunoglobulin-derived binding domain(s) and an antigen for which the immunoglobulin or protein is specific.
  • the strength, or affinity of immunological binding interactions can be expressed in terms of the dissociation constant (Ka) of the interaction, wherein a smaller Ka represents a greater affinity.
  • Immunological binding properties of selected polypeptides can be quantified using methods well known in the art.
  • One such method entails measuring the rates of antigenbinding site/antigen complex formation and dissociation, wherein those rates depend on the concentrations of the complex partners, the affinity of the interaction, and geometric parameters that equally influence the rate in both directions.
  • both the “on rate constant” (K on ) and the “off rate constant” (Koff) can be determined by calculation of the concentrations and the actual rates of association and dissociation.
  • K on the concentrations and the actual rates of association and dissociation.
  • An antibody or antigen-binding portion provided herein is said to specifically bind PD-L1 or CD3 when the equilibrium binding constant (Kd) is ⁇ 10 ⁇ M, preferably ⁇ 10 ⁇ M, more preferably ⁇ 10 ⁇ M, and most preferably ⁇ 100 pM to about 1 pM, as measured by assays such as radioligand binding assays or similar assays known to those skilled in the art.
  • Kd equilibrium binding constant
  • One method for determining the Ka of an antibody is by using surface plasmon resonance (SPR), typically using a biosensor system such as a Biacore® system.
  • the binding affinity of a protein provided herein may be within the range of 10 -5 Mto 10 -12 M.
  • the binding affinity of a protein provided herein is from 10 -6 M to 10 -12 M, from 10 -7 M to 10 -12 M, from 10 -8 M to 10 -12 M, from 10 -9 M to 10 -12 M, from 10 -5 M to 10’ 11 M, from 10 -6 M to 10’ 11 M, from 10 -7 M to 10 -11 M, from 10 -8 M to 10 -11 M, from 10 -9 M to 10 -11 M, from 10 -10 M to 10 -11 M, from 10 -5 M to 10 -10 M, from 10 -6 M to 10 -10 M, from 10 -7 M to 10 -10 M, from 10 -8 M to 10 -10 M, from 10 -9 M to 10" 10 M, from 10 -5 M to 10 -9 M, from 10 -6 M to 10 -9 M, from 10 -7 M to 10 -9 M, from 10 -8 M to 10 -9 M
  • a protein comprising a first polypeptide chain comprising a heavy chain and a second polypeptide chain comprising a light chain
  • the heavy chain comprises, in N-terminus to C-terminus order, an anti-PD-Ll heavy chain variable (VH) domain, a first CHI domain, a first linker, an anti-CD3 VH domain, and a second CHI domain
  • the light chain comprises, in N-terminus to C-terminus order, an anti-PD-Ll light chain variable (VL) domain, a first immunoglobulin light chain constant region, a second linker, an anti-CD3 VL domain, and a second immunoglobulin light chain constant region.
  • a protein comprising a first polypeptide chain comprising a heavy chain and a second polypeptide chain comprising a light chain
  • the heavy chain comprises, in N-terminus to C-terminus order, an anti-PD-Ll heavy chain variable (VH) domain, a first CHI domain, a first linker, an anti-CD3 light chain variable (VL) domain, and a first immunoglobulin light chain constant region
  • the light chain comprises, in N-terminus to C-terminus order, anti-PD-Ll VL domain, a second immunoglobulin light chain constant region, a second linker, an anti- CD3 VH domain, and a second CHI domain.
  • the heavy chain comprises in N-terminus to C-terminus order, the anti-PD-Ll VH domain, the first CHI domain, the first linker, the anti-CD3 VH domain, the second CHI domain, a hinge, a CH2 domain, and a CH3 domain.
  • the protein further comprises a third polypeptide chain comprising a hinge and a Fc region.
  • the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 124.
  • a protein comprising a first polypeptide chain comprising a heavy chain and a second polypeptide chain comprising a light chain
  • the heavy chain comprises, in N-terminus to C-terminus order, an anti-PD-Ll heavy chain variable (VH) domain, a first CHI domain, a first linker, an anti-CD3 VH domain, a second CHI domain, a first hinge, a first CH2 domain, and a first CH3 domain
  • the light chain comprises, in N-terminus to C-terminus order, an anti-PD-Ll light chain variable (VL) domain, a first immunoglobulin light chain constant region, a second linker, an anti-CD3 VL domain, a second immunoglobulin light chain constant region, a second hinge, a second CH2 domain, and a second CH3 domain.
  • the first linker comprises the amino acid sequence of any one of SEQ ID NOs: 1-12. In some embodiments, the first linker comprises an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of any one of SEQ ID NOs: 1-12.
  • the second linker comprises the amino acid sequence of any one of SEQ ID NOs: 1-12. In some embodiments, the second linker comprises an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of any one of SEQ ID NOs: 1-12.
  • the first linker comprises the amino acid sequence of any one of SEQ ID NOs: 1-12
  • the second linker comprises the amino acid sequence of any one of SEQ ID NOs: 1-12.
  • the first linker comprises an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of any one of SEQ ID NOs: 1-12
  • the second linker comprises an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of any one of SEQ ID NOs: 1-12.
  • the first linker is the same as the second linker. In some embodiments, the first linker is not the same as the second linker. [0089] In some embodiments, the anti-PD-Ll VH domain comprises a HCDR1 comprising the amino acid sequence of SEQ ID NO: 50. In some embodiments, the anti-PD-Ll VH domain comprises a HCDR2 comprising the amino acid sequence of SEQ ID NO: 51. In some embodiments, the anti-PD-Ll VH domain comprises a HCDR3 comprising the amino acid sequence of SEQ ID NO: 52.
  • the anti-PD-Ll VH domain comprises a HCDR1 comprising the amino acid sequence of SEQ ID NO: 20, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 21, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 22; and the anti-PD-Ll VL domain comprises a LCDR1 comprising the amino acid sequence of SEQ ID NO: 23, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 24, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 25.
  • the anti-PD-Ll VH domain comprises a HCDR1 comprising the amino acid sequence of SEQ ID NO: 20, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 21, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 22; and the anti-PD-Ll VL domain comprises at least one LCDR sequence selected from: a LCDR1 comprising the amino acid sequence of SEQ ID NO: 23, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 24, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 25.
  • the anti-PD-Ll VH domain comprises at least one HCDR sequence selected from: a HCDR1 comprising the amino acid sequence of SEQ ID NO: 20, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 21, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 22; and the anti-PD-Ll VL domain comprises a LCDR1 comprising the amino acid sequence of SEQ ID NO: 23, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 24, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 25.
  • the anti-CD3 VH domain comprises a HCDR1 comprising the amino acid sequence of SEQ ID NO: 26, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 27, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 29; and the anti-CD3 VL domain comprises a LCDR1 comprising the amino acid sequence of SEQ ID NO: 30, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 31, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 32.
  • the anti-CD3 VH domain comprises a HCDR1 comprising the amino acid sequence of SEQ ID NO: 26, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 27, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 29; and the anti-CD3 VL domain comprises at least one LCDR sequence selected from: a LCDR1 comprising the amino acid sequence of SEQ ID NO: 30, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 31, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 32.
  • the anti-CD3 VH domain comprises at least one HCDR sequence selected from: a HCDR1 comprising the amino acid sequence of SEQ ID NO: 26, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 27, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 29; and the anti-CD3 VL domain comprises a LCDR1 comprising the amino acid sequence of SEQ ID NO: 30, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 31, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 32.
  • the anti-CD3 VH domain comprises a HCDR1 comprising the amino acid sequence of SEQ ID NO: 26, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 28, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 29; and the anti-CD3 VL domain comprises a LCDR1 comprising the amino acid sequence of SEQ ID NO: 30, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 31, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 32.
  • the anti-CD3 VH domain comprises a HCDR1 comprising the amino acid sequence of SEQ ID NO: 26, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 28, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 29; and the anti-CD3 VL domain comprises at least one LCDR sequence selected from: a LCDR1 comprising the amino acid sequence of SEQ ID NO: 30, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 31, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 32.
  • the anti-CD3 VH domain comprises at least one HCDR sequence selected from: a HCDR1 comprising the amino acid sequence of SEQ ID NO: 26, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 28, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 29; and the anti-CD3 VL domain comprises a LCDR1 comprising the amino acid sequence of SEQ ID NO: 30, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 31, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 32.
  • the anti-PD-Ll VH domain comprises a HCDR1 comprising the amino acid sequence of SEQ ID NO: 20, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 21, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 22;
  • the anti-PD-Ll VL domain comprises a LCDR1 comprising the amino acid sequence of SEQ ID NO: 23, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 24, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 25;
  • the anti-CD3 VH domain comprises aHCDRl comprising the amino acid sequence of SEQ ID NO: 26, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 27, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 29; and
  • the anti-CD3 VL domain comprises a LCDR1 comprising the amino acid sequence of SEQ ID NO: 30, a LCDR2 comprising the amino acid sequence of SEQ
  • the anti-PD-Ll VH domain comprises a HCDR1 comprising the amino acid sequence of SEQ ID NO: 20, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 21, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 22;
  • the anti-PD-Ll VL domain comprises a LCDR1 comprising the amino acid sequence of SEQ ID NO: 23, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 24, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 25;
  • the anti-CD3 VH domain comprises aHCDRl comprising the amino acid sequence of SEQ ID NO: 26, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 28, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 29; and
  • the anti-CD3 VL domain comprises a LCDR1 comprising the amino acid sequence of SEQ ID NO: 30, a LCDR2 comprising the amino acid sequence of SEQ
  • a protein comprising a first polypeptide chain comprising a heavy chain and a second polypeptide chain comprising a light chain
  • the heavy chain comprises, in N-terminus to C-terminus order, an anti-PD-Ll heavy chain variable (VH) domain, a first CHI domain, a first linker, an anti-CD3 VH domain, and a second CHI domain
  • the light chain comprises, in N-terminus to C-terminus order, an anti-PD-Ll light chain variable (VL) domain, a first immunoglobulin light chain constant region, a second linker, an anti-CD3 VL domain, and a second immunoglobulin light chain constant region
  • the anti-PD-Ll VH domain comprises a HCDR1 comprising the amino acid sequence of SEQ ID NO: 20, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 21, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 22;
  • a protein comprising a first polypeptide chain comprising a heavy chain and a second polypeptide chain comprising a light chain
  • the heavy chain comprises, in N-terminus to C-terminus order, an anti-PD-Ll heavy chain variable (VH) domain, a first CHI domain, a first linker, an anti-CD3 VH domain, and a second CHI domain
  • the light chain comprises, in N-terminus to C-terminus order, an anti-PD-Ll light chain variable (VL) domain, a first immunoglobulin light chain constant region, a second linker, an anti-CD3 VL domain, and a second immunoglobulin light chain constant region
  • the anti-PD-Ll VH domain comprises a HCDR1 comprising the amino acid sequence of SEQ ID NO: 20, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 21, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 22;
  • the anti-PD-Ll VH domain comprises the amino acid sequence of any one of SEQ ID NOs: 33 and 54-107. In some embodiments, the anti- PD-Ll VH domain comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of any one of SEQ ID NOs: 33 and 54-107.
  • the anti-PD-Ll VL domain comprises the amino acid sequence of SEQ ID NO: 34. In some embodiments, the anti-PD-Ll VL domain comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 34.
  • the anti-PD-Ll VH domain comprises the amino acid sequence of any one of SEQ ID NOs: 33 and 54-107, and the anti-PD-Ll VL domain comprises the amino acid sequence of SEQ ID NO: 34.
  • the anti-CD3 VH domain comprises the amino acid sequence of any one of SEQ ID NOs: 44-48. In some embodiments, the anti-CD3 VH domain comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of any one of SEQ ID NOs: 44-48.
  • the anti-CD3 VL domain comprises the amino acid sequence of any one of SEQ ID NOs: 37-42. In some embodiments, the anti-CD3 VL domain comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of any one of SEQ ID NOs: 37-42.
  • the anti-CD3 VH domain comprises the amino acid sequence of any one of SEQ ID NOs: 44-48
  • the anti-CD3 VL domain comprises the amino acid sequence of any one of SEQ ID NOs: 37-42.
  • the heavy chain comprises the amino acid sequence of any one of SEQ ID NOs: 116-123, 129-132, 137-141, 142, 144, 146, 147, 148, 150, and 152.
  • the heavy chain comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of any one of SEQ ID NOs: 116-123, 129-132, 137-141, 142, 144, 146, 147, 148, 150, and 152.
  • the light chain comprises the amino acid sequence of any one of SEQ ID NOs: 53, 108-115, 125-128, and 133-136, 143, 145, 151, and 153.
  • the heavy chain comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of any one of SEQ ID NOs: 53, 108-115, 125-128, and 133-136, 143, 145, 151, and 153.
  • the heavy chain comprises the amino acid sequence of SEQ ID NO: 122
  • the light chain comprises the amino acid sequence of SEQ ID NO: 114
  • the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 124;
  • the heavy chain comprises the amino acid sequence of SEQ ID NO: 123
  • the light chain comprises the amino acid sequence of SEQ ID NO: 115
  • the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 124;
  • the heavy chain comprises the amino acid sequence of SEQ ID NO: 116
  • the light chain comprises the amino acid sequence of SEQ ID NO: 108
  • the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 124;
  • the heavy chain comprises the amino acid sequence of SEQ ID NO: 117
  • the light chain comprises the amino acid sequence of SEQ ID NO: 109
  • the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 124;
  • the heavy chain comprises the amino acid sequence of SEQ ID NO: 118
  • the light chain comprises the amino acid sequence of SEQ ID NO: 108
  • the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 124;
  • the heavy chain comprises the amino acid sequence of SEQ ID NO: 119
  • the light chain comprises the amino acid sequence of SEQ ID NO: 109
  • the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 124;
  • the heavy chain comprises the amino acid sequence of SEQ ID NO: 120, the light chain comprises the amino acid sequence of SEQ ID NO: 108, and the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 124;
  • the heavy chain comprises the amino acid sequence of SEQ ID NO: 116, the light chain comprises the amino acid sequence of SEQ ID NO: 110, and the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 124;
  • the heavy chain comprises the amino acid sequence of SEQ ID NO: 118
  • the light chain comprises the amino acid sequence of SEQ ID NO: 110
  • the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 124;
  • the heavy chain comprises the amino acid sequence of SEQ ID NO: 120
  • the light chain comprises the amino acid sequence of SEQ ID NO: 110
  • the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 124;
  • the heavy chain comprises the amino acid sequence of SEQ ID NO: 116
  • the light chain comprises the amino acid sequence of SEQ ID NO: 111
  • the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 124;
  • the heavy chain comprises the amino acid sequence of SEQ ID NO: 118
  • the light chain comprises the amino acid sequence of SEQ ID NO: 111
  • the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 124;
  • the heavy chain comprises the amino acid sequence of SEQ ID NO: 120
  • the light chain comprises the amino acid sequence of SEQ ID NO: 111
  • the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 124;
  • the heavy chain comprises the amino acid sequence of SEQ ID NO: 116
  • the light chain comprises the amino acid sequence of SEQ ID NO: 112
  • the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 124;
  • the heavy chain comprises the amino acid sequence of SEQ ID NO: 116
  • the light chain comprises the amino acid sequence of SEQ ID NO: 113
  • the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 124;
  • the heavy chain comprises the amino acid sequence of SEQ ID NO: 121
  • the light chain comprises the amino acid sequence of SEQ ID NO: 108
  • the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 124;
  • the heavy chain comprises the amino acid sequence of SEQ ID NO: 131
  • the light chain comprises the amino acid sequence of SEQ ID NO: 127
  • the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 124;
  • the heavy chain comprises the amino acid sequence of SEQ ID NO: 120
  • the light chain comprises the amino acid sequence of SEQ ID NO: 127
  • the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 124.
  • Table 9 Chain sequence combinations used to form illustrative LB proteins as described in FIG. 1 and based on sequences specified in Tables 7 and 8
  • a protein comprising a heavy chain and a light chain, wherein the heavy chain comprises an amino acid sequence provided herein, with 1, 2 or 3 conservative amino acid substitutions; and wherein the light chain comprises an amino acid sequence provided herein, with 1, 2 or 3 conservative amino acid substitutions.
  • conservative amino acid substitutions are made only in the FR sequences and not in the CDR sequences. In some embodiments, conservative amino acid substitutions are not made in the first linker or the second linker sequences.
  • a protein provided herein comprises an immunoglobulin heavy chain constant region at the C-terminus of the heavy chain. In some embodiments, a protein provided herein comprises an immunoglobulin heavy chain constant region at the C-termini of both the first polypeptide chain and the second polypeptide chain. In some embodiments, the immunoglobulin heavy chain constant region is IgG, IgE, IgM, IgD, IgA or IgY. In some embodiments, the immunoglobulin heavy chain constant region is IgGl, IgG2, IgG3, IgG4, IgAl or IgA2. In some embodiments, the immunoglobulin heavy chain constant region is IgGl.
  • the immunoglobulin heavy chain constant region is immunologically inert. In some embodiments, the immunoglobulin heavy chain constant region comprises one or more mutations to reduce or prevent FcyR binding, antibody- dependent cell-mediated cytotoxicity (ADCC) activity, antibody-dependent cellular phagocytosis (ADCP), and/or complement-dependent cytotoxicity (CDC) activity.
  • ADCC antibody-dependent cell-mediated cytotoxicity
  • ADCP antibody-dependent cellular phagocytosis
  • CDC complement-dependent cytotoxicity
  • the immunoglobulin heavy chain constant region is a wild-type human IgGl constant region, a wild-type human IgG2 constant region, a wild-type human IgG4 constant region, a human IgGl constant region comprising the amino acid substitutions L234A, L235A and G237A, a human IgGl constant region comprising the amino acid substitutions L234A, L235A, G237A and P331S or a human IgG4 constant region comprising the amino acid substitution S228P, wherein numbering is according to the EU index as in Kabat.
  • a position of an amino acid residue in a constant region of an immunoglobulin molecule is numbered according to the EU index as in Kabat (Ward et al., 1995 Therap. Immunol. 2:77-94).
  • the CH2 or CH3 regions may comprise sites to aid with pairing of the two polypeptide chains. Any suitable Fc heterodimerization technology may be used for pairing the polypeptide chains.
  • N-linked glycosylation sites are included in the CH2 regions.
  • Knobs and Holes mutations are included in the CH3 regions.
  • a protein provided herein may comprise an immunoglobulin light chain constant region that is a kappa light chain.
  • a kappa light chain comprises SEQ ID NO: 15.
  • a protein provided herein may comprise an immunoglobulin light chain constant region that is a lambda light chain.
  • a protein provided herein may comprise an immunoglobulin heavy chain constant region comprising an amino acid sequence of an Fc region of human IgG4, human IgG4(S228P), human IgG2, human IgGl, human IgGl effector null.
  • the human IgG4(S228P) Fc region comprises the following substitution compared to the wild-type human IgG4 Fc region: S228P.
  • the human IgGl effector null Fc region comprises the following substitutions compared to the wild-type human IgGl Fc region: L234A, L235 A and G237A.
  • a protein may comprise an immunoglobulin heavy chain constant region comprising the amino acid sequence of any one of SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, and SEQ ID NO: 19.
  • a protein may comprise an immunoglobulin heavy chain constant region comprising an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of any one of SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, and SEQ ID NO: 19.
  • a protein may comprise a hinge (e.g., a Fc hinge) that is a wild-type human IgGl hinge, wild-type human IgG2 hinge, wild-type human IgG3 hinge, or wild-type human IgG4 hinge.
  • a protein may comprise an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of a wild-type human IgGl hinge, wild-type human IgG2 hinge, wild-type human IgG3 hinge, or wild-type human IgG4 hinge.
  • a protein may comprise a hinge comprising an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of the hinge sequence in any one of SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, and SEQ ID NO: 19.
  • an immunoconjugate comprising a protein disclosed herein linked to a therapeutic agent.
  • the therapeutic agent is a cytotoxin, a radioisotope, a chemotherapeutic agent, an immunomodulatory agent, a cytostatic enzyme, a cytolytic enzyme, a therapeutic nucleic acid, an anti-angiogenic agent, an anti-proliferative agent, or a pro-apoptotic agent.
  • Suitable therapeutic agents include, but are not limited to, immunomodulatory agents, cytotoxins, radioisotopes, chemotherapeutic agents, anti- angiogenic agents, antiproliferative agents, pro-apoptotic agents, and cytostatic and cytolytic enzymes (for example, RNAses).
  • Further therapeutic agents include a therapeutic nucleic acid, such as a gene encoding an immunomodulatory agent, an anti- angiogenic agent, an anti-proliferative agent, or a pro-apoptotic agent. These drug descriptors are not mutually exclusive, and thus a therapeutic agent may be described using one or more of the above terms.
  • Suitable therapeutic agents for use in immunoconjugates include, but are not limited to, JAK kinase inhibitors, taxanes, maytansines, CC-1065 and the duocarmycins, the calicheamicins and other enediynes, and the auristatins.
  • Other examples include the anti-folates, vinca alkaloids, and the anthracy clines.
  • Plant toxins, other bioactive proteins, enzymes (i.e., ADEPT), radioisotopes, photosensitizers may also be used in immunoconjugates.
  • conjugates can be made using secondary carriers as the cytotoxic agent, such as liposomes or polymers
  • Suitable cytotoxins include an agent that inhibits or prevents the function of cells and/or results in destruction of cells.
  • Representative cytotoxins include antibiotics, inhibitors of tubulin polymerization, alkylating agents that bind to and disrupt DNA, and agents that disrupt protein synthesis or the function of essential cellular proteins such as protein kinases, phosphatases, topoisomerases, enzymes, and cyclins.
  • Representative cytotoxins include, but are not limited to, doxorubicin, daunorubicin, idarubicin, aclarubicin, zorubicin, mitoxantrone, epirubicin, carubicin, nogalamycin, menogaril, pitarubicin, valrubicin, cytarabine, gemcitabine, trifluridine, ancitabine, enocitabine, azacitidine, doxifluhdine, pentostatin, broxuhdine, capecitabine, cladhbine, decitabine, floxuhdine, fludarabine, gougerotin, puromycin, tegafur, tiazofuhn, adhamycin, cisplatin, carboplatin, cyclophosphamide, dacarbazine, vinblastine, vincristine, mitoxantrone, bleomycin, mechlorethamine, prednis
  • Suitable immunomodulatory agents include anti -hormones that block hormone action on tumors and immunosuppressive agents that suppress cytokine production, down-regulate self-antigen expression, or mask MHC antigens.
  • the activatable proteins provided herein can be incorporated into pharmaceutical compositions suitable for administration.
  • Such compositions typically comprise a protein (or an immunoconjugate comprising said protein), and a pharmaceutically acceptable carrier.
  • Such compositions typically comprise a protein (or an immunoconjugate comprising said protein), and a pharmaceutically acceptable carrier, diluent or excipient.
  • Such materials should be non-toxic and should not interfere with the efficacy of the protein.
  • the precise nature of the carrier or other material will depend on the route of administration, which may be by injection, bolus, infusion, or any other suitable route, as discussed below.
  • the term “pharmaceutically acceptable” refers to molecular entities and compositions that do not generally produce allergic or other serious adverse reactions when administered using routes well known in the art. Molecular entities and compositions approved by a regulatory agency of the U.S. federal or state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans are considered to be “pharmaceutically acceptable.”
  • pharmaceutically acceptable carrier is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration.
  • Suitable carriers are described in the most recent edition of Remington's Pharmaceutical Sciences, a standard reference text in the field, which is incorporated herein by reference.
  • Some examples of such carriers or diluents include, but are not limited to, water, saline, Ringer's solutions, dextrose solution, and 5% human serum albumin.
  • Liposomes and non-aqueous vehicles such as fixed oils may also be used.
  • the use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.
  • a pharmaceutically acceptable carrier, diluent or excipient may be a compound or a combination of compounds that does not provoke secondary reactions and that allows, for example, facilitation of the administration of the protein, an increase in its lifespan and/or in its efficacy in the body or an increase in its solubility in solution.
  • a pharmaceutical composition disclosed herein may be formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (i.e., topical), transmucosal, and rectal administration.
  • Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfate; chelating agents such as ethylenediaminetetraacetic acid (EDTA); buffers such as acetates, citrates or phosphates, and agents for the adjustment of tonicity such as sodium chloride or dextrose.
  • the pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide.
  • the parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
  • compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion.
  • suitable carriers include physiological saline, bacteriostatic water, Cremophor EL® (BASF, Parsippany, NJ) or phosphate buffered saline (PBS).
  • the composition must be sterile and should be fluid to the extent that easy syringeability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof.
  • the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
  • Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like.
  • isotonic agents for example, sugars, polyalcohols such as mannitol, sorbitol, sodium chloride in the composition.
  • Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.
  • Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization.
  • dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above.
  • methods of preparation are vacuum drying and freeze-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
  • Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition.
  • the tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primojel®, or com starch; a lubricant such as magnesium stearate; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
  • a binder such as microcrystalline cellulose, gum tragacanth or gelatin
  • an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primojel®, or com starch
  • a lubricant such as magnesium stearate
  • a glidant such as colloidal silicon dioxide
  • a sweetening agent such
  • the compounds may be delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, e g., a gas such as carbon dioxide, or a nebulizer.
  • a suitable propellant e g., a gas such as carbon dioxide, or a nebulizer.
  • Systemic administration can also be by transmucosal or trans dermal means.
  • penetrants appropriate to the barrier to be permeated are used in the formulation.
  • penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives.
  • Transmucosal administration can be accomplished through the use of nasal sprays or suppositories.
  • the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.
  • the pharmaceutical agents can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.
  • suppositories e.g., with conventional suppository bases such as cocoa butter and other glycerides
  • retention enemas for rectal delivery.
  • the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems.
  • a controlled release formulation including implants and microencapsulated delivery systems.
  • Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially. Liposomal suspensions can also be used as pharmaceutically acceptable carriers.
  • Dosage unit form refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
  • the specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.
  • the protein may be provided in a lyophilized form for reconstitution prior to administration.
  • lyophilized antibody molecules may be reconstituted in sterile water and mixed with saline prior to administration to an individual.
  • compositions provided herein can be included in a container, pack, or dispenser together with instructions for administration.
  • nucleic acid molecule e.g., an isolated nucleic acid molecule
  • an amino acid sequence of a protein disclosed herein or an amino acid sequence of a (i) VH domain, (ii) a VL domain, or (iii) both a VH domain and a VL domain of a protein).
  • nucleic acid molecule e.g., an isolated nucleic acid molecule
  • encoding (i) a heavy chain, (ii) a light chain, or (iii) both a heavy chain and a light chain of a protein disclosed herein.
  • nucleic acid molecule e.g., an isolated nucleic acid molecule
  • a nucleic acid molecule encoding (i) a first polypeptide chain, (ii) a second polypeptide chain, or (iii) both a first polypeptide chain and a second polypeptide chain of a protein disclosed herein.
  • a nucleic acid molecule further encodes a third polypeptide chain (e.g., a third polypeptide chain comprising a hinge, a CH2 domain, and a CH3 domain).
  • a nucleic acid molecule encoding a VH domain, a VL domain, a heavy chain, a light chain, a first polypeptide chain, or a second polypeptide chain comprises a signal sequence (or encodes a leader peptide).
  • a nucleic acid molecule encoding a VH domain, a VL domain, a heavy chain, a light chain, a first polypeptide chain, or a second polypeptide chain does not comprise a signal sequence (or does not encode a leader peptide).
  • an expression vector comprising a nucleic acid molecule described herein.
  • a nucleic acid molecule is operatively linked to one or more regulatory sequences suitable for expression of the nucleic acid segment in a host cell.
  • an expression vector comprises sequences that mediate replication and comprises one or more selectable markers.
  • vector means a construct that is capable of delivering, and, preferably, expressing, one or more gene(s) or sequence(s) of interest in a host cell.
  • vectors include, but are not limited to, viral vectors, naked DNA or RNA expression vectors, plasmid, cosmid or phage vectors, DNA or RNA expression vectors associated with cationic condensing agents, DNA or RNA expression vectors encapsulated in liposomes, and certain eukaryotic cells, such as producer cells.
  • a recombinant host cell comprising an expression vector or a nucleic acid molecule disclosed herein.
  • a “host cell” includes an individual cell, a cell line or cell culture that can be or has been a recipient for vector(s) for incorporation of polynucleotide inserts.
  • Host cells include progeny of a single host cell. The progeny may not necessarily be completely identical (in morphology or in genomic DNA complement) to the original parent cell due to natural, accidental, or deliberate mutation.
  • An expression vector can be transfected into a host cell by standard techniques. Non-limiting examples include electroporation, calcium-phosphate precipitation, DEAE-dextran transfection and the like.
  • a recombinant host cell comprises a single vector or a single nucleic acid molecule encoding both a heavy chain and a light chain of a protein disclosed herein. In some embodiments, a recombinant host cell comprises (i) a first vector or a first nucleic acid molecule encoding a heavy chain of a protein disclosed herein and (ii) a second vector or a second nucleic acid molecule encoding a light chain of a protein disclosed herein. [0142] Protein molecules of the invention, or portions thereof, can be produced using techniques well known in the art, for example, recombinant technologies, phage display technologies, synthetic technologies, computational technologies or combinations of such technologies or other technologies readily known in the art.
  • a method for producing a protein disclosed herein comprising: culturing a recombinant host cell comprising an expression vector described herein under conditions whereby the nucleic acid segment is expressed, thereby producing the protein.
  • the protein may then be isolated from the host cell or culture.
  • a method of producing a protein comprising: culturing a recombinant host cell comprising an expression vector disclosed herein under conditions whereby the nucleic acid molecule is expressed, thereby producing the protein; and isolating the protein from the host cell or culture.
  • Proteins disclosed herein can be produced by any of a variety of methods known to those skilled in the art. In certain embodiments, proteins disclosed herein can be produced recombinantly. For example, nucleic acid sequences encoding one or more of the heavy chains or light chains provided herein, or portions thereof, may be introduced into a bacterial cell (e.g., E. coli, B. subtilis) or a eukaryotic cell (e.g, a yeast such as 5. cerevisiae.
  • bacterial cell e.g., E. coli, B. subtilis
  • a eukaryotic cell e.g, a yeast such as 5. cerevisiae.
  • light chain proteins and heavy chain proteins are produced in a cell with a signal sequence that is removed upon production of a mature protein disclosed herein.
  • An activatable protein, immunoconjugate, or pharmaceutical composition disclosed herein may be used in a method of treatment of the human or animal body, including prophylactic or preventative treatment (e.g., treatment before the onset of a condition in a subject to reduce the risk of the condition occurring in the subject; delay its onset; or reduce its severity after onset).
  • the method of treatment may comprise administering the protein, immunoconjugate, or pharmaceutical composition to a subject in need thereof.
  • an anti-cancer immune response is a T cell response.
  • an anti-cancer immune response is a complement response.
  • a method for treating cancer in a subject comprising administering to the subject a therapeutically effective amount of a protein, an immunoconjugate, or a pharmaceutical composition disclosed herein.
  • a method for ameliorating a symptom of cancer in a subject comprising administering to the subject a therapeutically effective amount of a protein, immunoconjugate, or a pharmaceutical composition disclosed herein.
  • a method for reducing the size of a tumor in a subject comprising administering to the subject a therapeutically effective amount of a protein, an immunoconjugate, or a pharmaceutical composition disclosed herein.
  • a method for inhibiting the growth of a tumor in a subject comprising administering to the subject a therapeutically effective amount of a protein, an immunoconjugate, or a pharmaceutical composition disclosed herein.
  • a protein, an immunoconjugate, or a pharmaceutical composition disclosed herein for use in enhancing an anti-cancer immune response in a subject.
  • a protein, an immunoconjugate, or a pharmaceutical composition disclosed herein for use in treating cancer in a subject.
  • the cancer is gastrointestinal stromal cancer (GIST), pancreatic cancer, skin cancer, melanoma, breast cancer, lung cancer, bronchial cancer, colorectal cancer, prostate cancer, stomach cancer, ovarian cancer, urinary bladder cancer, brain cancer, central nervous system cancer, peripheral nervous system cancer, esophageal cancer, cervical cancer, uterine cancer, endometrial cancer, cancer of the oral cavity or pharynx, liver cancer, kidney cancer, renal cell carcinoma, testicular cancer, biliary tract cancer, small bowel cancer, appendix cancer, salivary gland cancer, thyroid cancer, adrenal gland cancer, osteosarcoma, chondrosarcoma, or cancer of hematological tissues.
  • GIST gastrointestinal stromal cancer
  • pancreatic cancer skin cancer, melanoma, breast cancer, lung cancer, bronchial cancer, colorectal cancer, prostate cancer, stomach cancer, ovarian cancer, urinary bladder cancer, brain cancer, central nervous system cancer, peripheral nervous system cancer, esophageal cancer
  • the cancer is a solid tumor. In some embodiments, the cancer is a hematological cancer.
  • a cancer of hematological tissues is a lymphoma. In some embodiments, the cancer is mantle cell lymphoma, acute lymphoblastic leukemia, chronic lymphocytic leukemia, Non-Hodgkin’s lymphoma, Hodgkin’s lymphoma, acute myeloid leukemia (AML), B-lymphoid leukemia, blastic plasmocytoid dendritic neoplasm (BPDCN), or hairy cell leukemia.
  • the term “effective amount” or “therapeutically effective amount” refers to the amount of a pharmaceutical agent, e.g., a protein, an immunoconjugate, or a pharmaceutical composition disclosed herein, which is sufficient to reduce or ameliorate the severity and/or duration of a cancer, or one or more symptoms thereof, prevent the advancement of a disease, cause regression of a disease, prevent the recurrence, development, onset or progression of one or more symptoms associated with a disease, or enhance or improve the prophylactic or therapeutic effect(s) of another related therapy (e.g., prophylactic or therapeutic agent) for a cancer.
  • a pharmaceutical agent e.g., a protein, an immunoconjugate, or a pharmaceutical composition disclosed herein
  • the actual amount administered, and rate and time-course of administration will depend on the nature and severity of what is being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the composition, the method of administration, the scheduling of administration and other factors known to medical practitioners. Prescription of treatment, e.g., decisions on dosage etc., is within the responsibility of general practitioners and other medical doctors and may depend on the severity of the symptoms and/or progression of a disease being treated. Appropriate doses of antibody-based protein molecules are well known in the art (Ledermann J. A. et al., 1991, Int. J. Cancer 47: 659-664; Bagshawe K.D.
  • a therapeutically effective amount or suitable dose of an antibody-based protein molecule may be determined by comparing its in vitro activity and in vivo activity in an animal model. Methods for extrapolation of effective dosages in mice and other test animals to humans are known. The precise dose will depend upon a number of factors, including whether the antibody-based protein is for prevention or for treatment, the size and location of the area to be treated, the precise nature of the antibody-based protein, and the nature of any detectable label or other molecule attached to the antibody-based protein.
  • a typical protein dose will be in the range 100 pg to 1 g for systemic applications, and 1 pg to 1 mg for intradermal injection.
  • An initial higher loading dose, followed by one or more lower doses, may be administered.
  • the protein is an IgGl or IgG4 isotype.
  • a dose for a single treatment of an adult subject may be proportionally adjusted for children and infants. Treatments may be repeated at daily, twice-weekly, weekly or monthly intervals, at the discretion of the physician.
  • the treatment schedule for a subject may be dependent on the pharmacokinetic and pharmacodynamic properties of the protein composition, the route of administration and the nature of the condition being treated.
  • Treatment may be periodic, and the period between administrations may be about two weeks or more, e.g., about three weeks or more, about four weeks or more, about once a month or more, about five weeks or more, or about six weeks or more. For example, treatment may be every two to four weeks or every four to eight weeks. Treatment may be given before, and/or after surgery, and/or may be administered or applied directly at the anatomical site of surgical treatment or invasive procedure. Suitable formulations and routes of administration are described above.
  • a protein, an immunoconjugate, or a pharmaceutical composition disclosed herein may be administered as a sub-cutaneous injection.
  • Subcutaneous injections may be administered using an auto-injector, for example for long term prophylaxis/treatment.
  • the therapeutic effect of a protein, an immunoconjugate, or a pharmaceutical composition disclosed herein may persist for several half-lives, depending on the dose.
  • the therapeutic effect of a single dose of a protein, an immunoconjugate, or a pharmaceutical composition disclosed herein may persist in a subject for 1 month or more, 2 months or more, 3 months or more, 4 months or more, 5 months or more, or 6 months or more.
  • a subject may be treated with a protein, an immunoconjugate, or a pharmaceutical composition disclosed herein and an additional therapeutic agent or therapy that is used to treat a cancer or a symptom or complication of a cancer.
  • the protein, immunoconjugate, or pharmaceutical composition disclosed herein and the additional therapeutic agent or therapy may be administered simultaneously or sequentially.
  • a subject is a mammal, a human, a non-human primate, a pig, a horse, a cow, a dog, a cat, a guinea pig, a mouse or a rat.
  • a subject is an adult human.
  • a subject is a pediatric human.
  • a human subject is 16 years of age or older.
  • a human subject is 18 years of age or older.
  • a human subject is less than 16 years of age.
  • a human subject is less than 18 years of age.
  • a protein, an immunoconjugate, or a pharmaceutical composition disclosed herein for use in the treatment of a disease or a disorder.
  • a protein, an immunoconjugate, or a pharmaceutical composition disclosed herein for use as a medicament.
  • the terms “hinge linker”, “linker”, “hinge”, “first linker”, “second linker”, “lower hinge linker” (“LHL”), “inter-Fab linker”, and derivations thereof, in plural or singular form refer to a sequence, for example derived from an immunoglobulin hinge region, that can link two polypeptides, for example polypeptides of different Fab regions, and is separate from any hinge sequence in an immunoglobulin hinge region that may be part of a protein of the present invention.
  • LB protein refers to LockBody proteins of the instant invention with a structure as defined in FIG. 1.
  • sequence identity refers to the extent to which two optimally aligned polynucleotides or polypeptide sequences are invariant throughout a window of alignment of residues, e.g., nucleotides or amino acids.
  • An “identity fraction” for aligned segments of a test sequence and a reference sequence is the number of identical residues which are shared by the two aligned sequences divided by the total number of residues in the reference sequence segment, i.e., the entire reference sequence or a smaller defined part of the reference sequence. “Percent identity” is the identity fraction times 100.
  • Percentage identity can be calculated using the alignment program Clustal Omega, available at ebi.ac.uk/Tools/msa/clustalo using default parameters. See, Sievers et al., “Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega” (2011 October 11) Molecular Systems Biology 7:539. For the purposes of calculating identity to the sequence, extensions, such as tags, are not included.
  • HCDR refers to a heavy chain complementarity determining region.
  • LCDR refers to a light chain complementarity determining region.
  • amino-terminal N-terminus
  • carboxyl-terminal C- terminus
  • amino-terminal N-terminus
  • carboxyl-terminal C- terminus
  • these terms are used with reference to a particular sequence or portion of a polypeptide to denote proximity or relative position.
  • a certain sequence positioned carboxyl-terminal to a reference sequence within a polypeptide is located proximal to the carboxyl-terminus of the reference sequence but is not necessarily at the carboxyl-terminus of the complete polypeptide.
  • the term “conservative substitution” refers to replacement of an amino acid with another amino acid which does not significantly deleteriously change the functional activity.
  • a preferred example of a “conservative substitution” is the replacement of one amino acid with another amino acid which has a value ⁇ 0 in the following BLOSUM 62 substitution matrix (see Henikoff & Henikoff, 1992, PNAS 89: 10915-10919):
  • immunoconjugate refer to a protein of the disclosure that is conjugated to a cytotoxic, a cytostatic and/or a therapeutic agent.
  • isolated molecule (where the molecule is, for example, a protein, a nucleic acid, a polynucleotide, or an antibody) is a molecule that by virtue of its origin or source of derivation (1) is not associated with naturally associated components that accompany it in its native state, (2) is substantially free of other molecules from the same species (3) is expressed by a cell from a different species, or (4) does not occur in nature.
  • a molecule that is chemically synthesized, or expressed in a cellular system different from the cell from which it naturally originates will be “isolated” from its naturally associated components.
  • a molecule also may be rendered substantially free of naturally associated components by isolation, using purification techniques well known in the art.
  • Molecule purity or homogeneity may be assayed by a number of means well known in the art.
  • the purity of a polypeptide sample may be assayed using polyacrylamide gel electrophoresis and staining of the gel to visualize the polypeptide using techniques well known in the art.
  • higher resolution may be provided by using HPLC or other means well known in the art for purification.
  • inhibitor means the ability of the protein to substantially antagonize, prohibit, prevent, restrain, slow, disrupt, eliminate, stop, reduce or reverse for example progression, strength, or severity of that which is being inhibited including, but not limited to, the binding of PD-L1 to PD-1, or the binding of CD3 to the T-cell receptor (TCR).
  • TCR T-cell receptor
  • the terms “treat,” “treating” or “treatment of’ mean that the severity of the subject's condition is reduced, at least partially improved or stabilized and/or that some alleviation, mitigation, decrease or stabilization in at least one clinical symptom is achieved and/or there is a delay in the progression of the disease or disorder.
  • PD-L1 is also known as programmed cell death ligand 1, CD274, B7-H, B7H1, PDCD1L1, PDCD1LG1, PDL1, and hPD-Ll.
  • Illustrative PD-L1 amino acid sequences are provided as SEQ ID NO: 35 and SEQ ID NO: 36.
  • CD3 is also known as cluster of differentiation 3.
  • CD3 is a multimeric protein complex.
  • CD3 is composed of four distinct polypeptide chains; epsilon (e), gamma (y), delta ( ⁇ ) and zeta ( ⁇ )
  • the terms “prevent,” “preventing” and “prevention” refer to prevention and/or delay of the onset of a disease, disorder and/or a clinical symptom(s) in a subject and/or a reduction in the severity of the onset of the disease, disorder and/or clinical symptom(s) relative to what would occur in the absence of the compositions and/or methods described herein.
  • the prevention can be complete, e.g, the total absence of the disease, disorder and/or clinical symptom(s).
  • the prevention can also be partial, such that the occurrence of the disease, disorder and/or clinical symptom(s) in the subject and/or the severity of onset is less than what would occur in the absence of the compositions and/or methods described herein.
  • a “therapeutically effective amount” is the amount of a protein or a pharmaceutical composition provided herein that is effective to treat a disease or disorder in a subject or to ameliorate a sign or symptom thereof.
  • the “therapeutically effective amount” may vary depending, for example, on the disease and/or symptoms of the disease, severity of the disease and/or symptoms of the disease or disorder, the age, weight, and/or health of the patient to be treated, and the judgment of the prescribing physician.
  • Polypeptide-encoding DNA sequences were cloned via restriction-ligation cloning into separate human IgGl heavy and light-chain constant region-encoding expression cassettes in separate plasmid vectors, to create activatable constructs for expression.
  • Proteins were expressed in CHO cells and purified from culture supernatants via a combination of Protein A affinity chromatography (ProA), Ion Exchange Chromatography (IEX) and/or Size Exclusion Chromatography (SEC). Purified proteins were characterized by SEC, SDS-PAGE and mass spectrometry.
  • MMP Matrix Metalloprotease
  • Jurkat cells were harvested, counted and washed once with PBS, before staining with Zombie UV viability dye diluted 1 in 1000 in PBS for 30 minutes at room temperature (RT). Induction was determined by calculating the ratio of the sample RLU/RLU in the absence of antibody following subtraction of background luminescence signal.
  • Cells were washed with staining buffer (0.1% BSA in PBS), resuspended in staining buffer and separated into test aliquots. Cells were incubated with LB proteins at the indicated times for 30min on ice. Cells were washed with staining buffer twice, before incubating with secondary antibody, or staining buffer alone, for 60 minutes on ice.
  • Fab samples were diluted to 1.0 pg/mL in running buffer and at the start of each cycle loaded onto F c 2, of a series S CM5 chip (Cytiva, Marlborough, USA) previously coupled with an anti- human Fab capture antibody (Cytiva, Marlborough, USA) using standard amine chemistry.
  • Ligand was captured at a flow rate of 10 pl/min to give an immobilization level (RL) of - 110 RU. The surface was then allowed to stabilize.
  • Multi-cycle kinetic data was obtained using either human or cynomolgus protein as the analyte injected at a flow rate of 30 pl/min to try and minimize any potential mass transfer effects.
  • An eight point, two-fold dilution range from 100.0 ⁇ M to 0.78 ⁇ M was prepared in running buffer for antigens. For each concentration, the association phases were monitored for 240 seconds, and the dissociation phase was measured for 600 seconds. Regeneration of the sensor chip surface was conducted between cycles using 10 mM glycine pH 2.1. Multiple repeats of a blank and of antigen were programmed into the kinetic run, in order to check the stability of both the surface and analyte over the kinetic cycles. The signal from the reference F C 1 (no ligand captured) was subtracted from that of F c 2 to correct for bulk effect and differences in non-specific binding to a reference surface.
  • the signal from each blank run (ligand captured but no antigen) was subtracted to correct for differences in surface stability. Binding was analysed using 1:1 binding analysis due to the high affinity interaction between the antibody and antigen. The data was analysed using a procedure referred to as double referencing. This refers to the process of first subtracting the reference channel response (Fd) and then subtracting the zero concentration sensorgram to compensate for bulk effects, baseline drift and small differences between the reference and the active channel.
  • Fd reference channel response
  • Respective tumor cells were counted and seeded into the appropriate 96-well plates and left to adhere for approximately 24h.
  • PBMC cells were isolated from whole blood by centrifugation followed immediately by T cell isolation. To this end, PBMCs were incubated with a Pan T cell MicroBead cocktail and subsequently applied to a MACS separator column. Flow through cells representing enriched T cells were collected and diluted to desired levels.
  • LB proteins or buffer with appropriate concentrations of Annexin V stain were added to adherent tumor target cells followed immediately by T cells and placement of plates into the Incucyte® S3 Live-Cell Analysis System incubator. Scanning intervals were set at every 4h for 72 - 96h. Annexin V data was normalized against Buffer/T- cell/Tumor cell signals before plotting.
  • mice Humanized mice were generated by myeloablation, transplantation of hCD34+ HSCs into NCG mice and subsequent myeloid cytokines boost.
  • MDA-MB-231 TNBC cells were implanted and grown to a mean tumor volume of 80 mm 3 . Mice were then randomized and treated with either IgG isotype control antibody, atezolizumab or LB proteins at indicated doses by intraperitoneal injection, every 3 days, up to eight times. Tumor size was measured every 3 or 4 days using a caliper and mean values were plotted using Graphpad Prism.
  • Table 11 Alignment of AA19-127 of full lengths huPD-Ll and cynomolgus PD-
  • Mutations were selected if a negative (favorable) ddG affinity to cyno PD-L1 was calculated for a variant and the ddG affinity was unchanged or changed only slightly improved for the same variant binding to human PD-L1.
  • a set of 54 variants over 13 residue positions at the paratope of VH of BMS-936559 with PD-L1 were generated, as shown in Table 6. These 54 variants were produced as Fab proteins by transient transfection of CHO cells, then purified using CHI affinity purification. After purification, uniformity was assessed by analytical SEC (Table 12) and proteins with purities > 87% were further evaluated for binding to human and cyno PD-L1 in SPR
  • Table 13 depicts SPR binding result of selected anti-PD-Ll variants to human and cyno PD-L1 protein.
  • WT affinities were determined as KD (M) 4.4E-10 for human PD-L1 while cyno PD-L1 affinity is approximately lOfold lower at KD (M) 7.9E-9.
  • Mut-6, -23, -43 showed increased affinities to human and cyno PD-L1, while Mut-50 showed increased affinity to human PD-L1 only.
  • Mut-48 and Mut-49 were affinity improved to cyno, but not human, PD-L1 relative to WT.
  • DNA cassettes for each construct type were designed using combinations of the anti-PD-Ll variable domain, constant domain and linker sequences found in Table 1, in combination with the murine or humanized variable domain variants of the anti-CD3 antibody SP34, as shown in Table 2.
  • Table 2 To ensure the fitness of the SP34-derived domains for the structural format of these proteins, a series of novel SP34 humanization variants were tested alongside known SP34 V domain sequences for the murine and humanized forms as controls (Table 2). These humanized variants were then combined with PD-L1 variable domains, constant domains and linkers to form full-length heavy and light chain sequences (Table 3).
  • variable domain sequences used in the protein construct disclosed herein are the variable domain sequences provided in U.S. 7,943,743 B2 and Table 5 and Table 6.
  • the proteins were produced by transient transfection of CHO cells, then purified by proA, IEX and/or SEC. After the ProA step, proteins were examined for yield and uniformity by SEC (Table 14). Fully purified proteins demonstrated high purity (>95%) and uniformity by analytical SEC, demonstrating that the best-behaved constructs can be expressed and purified as an intact, stable product, in a single process.
  • Table 14 Productivity analyses for selected LB proteins, sequence combinations as shown in Table 9
  • FIG. 5A shows digestion profiles of exemplar LB proteins (LB204, 206, 208, 209, 210, 213 and 220). Intact proteins showed the expected band patterns in reducing and non-reducing SDS PAGE with one predominant band at 150kDa visible in non-reducing, and 3 chains visible at 75kDa (LB heavy chain), 50kDa (LB light chain) and ⁇ 30kDa (Fc Stump) in reducing gels.
  • Selected LB proteins were then tested for CD3 activation signal in mixed cell culture assay using the human PD-L1+ cell line MDA-MB-231 and a Jurkat cell line engineered to provide reporter signal for human CD3 activation (FIG. 3 A - FIG.3G).
  • This assay therefore tests the ability of molecules to bind the cell surface of the MDA- MB-231 cell line (through PD-L1 for test articles or Her2 for the BiTE control protein), and to activate CD3 in the Jurkat reporter line through trans presentation of the CD3 binding domains.
  • the Her2/CD3 BiTE positive control protein induced strong, concentration dependent CD3 activation, while the IgGl isotype negative control did not induce any signal.
  • the anti CD3 SP34 humanization V domain variants contained in LB206 and LB213 were then characterized further in Fab and IgG formats.
  • SPR surface plasmon resonance
  • Fab proteins were used to confirm binding to commercially available human and cyno CD3 ⁇ heterodimer peptides (Fig 4A and B). While KD values were calculated as 29 ⁇ M and 46 ⁇ M respectively, the off rate of Anti- CD3-Fab- 001 was notably different from Anti- CD3-Fab-002 (4.7xl0‘ 3 vs 2.0xl0 -2 ) against human CD3 ⁇ heterodimer.
  • purified IgGs of CD3-IgG00-l and CD3-IgG- 002 showed no difference in apparent affinities in a binding ELISA to the same commercially available human and cyno CD3 ⁇ heterodimer proteins (FIG. 4C).
  • purified IgG proteins were tested for CD3 activation signal in a Jurkat cell line engineered to provide reporter signal for human CD3 activation (FIG. 4D). This assay tested the ability of the new humanization variants to activate CD3 in the Jurkat reporter cell line in direct comparison to the mouse SP34 IgG molecule.
  • Anti- CD3-IgG-001 displays a similar activation ability to SP34 (EC50 of either molecule in this assay was 0.2 ⁇ M) in the Jurkat reporter cell line, while Anti- CD3- IgG-002 showed an approximately 5-fold lower apparent EC50 in this assay (EC50 0.9 ⁇ M).
  • these results demonstrated that CD3 dependent agonistic property of SP34 is preserved in Anti- CD3-IgG-001 humanization, while anti-CD3- IgG-002 showed a 5-fold lower agonistic potential in Jurkat reporter cells, in keeping with the lower KD and faster Kd rate observed in SPR analysis.
  • FIG. 5 A shows digestion profiles of exemplar LB proteins (LB204, 206, 208, 209, 210, 213, 220). Intact proteins showed the expected band patterns in reducing and non-reducing SDS PAGE with one predominant band at 150kDa visible in non-reducing, and 3 chains visible at 75kDa (LB heavy chain), 50kDa (LB light chain) and ⁇ 30kDa (Fc Stump) in reducing gels (FIG 5 A).
  • LB217, LB218 and LB220 were tested for CD3 activation signal in mixed cell culture assay using the human PD-L1+ cell line MDA-MB-231 and a Jurkat cell line engineered to provide reporter signal for human CD3 activation (FIG. 6A - FIG. 6C).
  • IgGl isotype negative control did not induce any signal while all test items exhibited low CD3 activation signal at Oh MMP12 incubation time (i.e., intact, uncleaved protein), demonstrating that the SP34 domains which bind CD3 have minimized ability to bind CD3 in all constructs.
  • luciferase signal in Jurkat reporter cells disappeared rapidly with increasing MMP12 incubation time (0.5 vs Ih) (FIG. 6C) compared to LB217 (FIG. 6A) and LB218 (FIG. 6B).
  • LB217 containing humanized CD3 variable domains based on LB206 showed the highest maximal signal compared to LB213 based CD3 variable domain containing proteins LB218 and LB220.
  • binding ELIS As to recombinant human and cyno CD3 ⁇ heterodimers as well as huPD-Ll domain were conducted with exemplary proteins (LB206, LB213, LB220; FIG 7). Binding signals on both CD3 orthologues confirmed that CD3 binding is greatly diminished in fully intact proteins but strongly increased after incubation with MMP12 at 37°C at the indicated times. In contrast, huPD-Ll binding of LB proteins is not affected by incubation with MMP12 for up to 15min but then reduces overtime.
  • FIG. 7A shows ELISA binding of intact or 5min MMP12 incubated LB206 protein to human PD-L1 with atezolizumab as positive control or IgGl isotype as negative control (no signal). Intact and MMP12 treated LB206 bind to PD-L1 to a similar level. Binding to PD-L1 appears lower than atezolizumab, consistent with one-arm LB protein structure and to two-arm IgG atezolizumab.
  • FIG. 7A shows ELISA binding of intact or 5min MMP12 incubated LB206 protein to human PD-L1 with atezolizumab as positive control or IgGl isotype as negative control (no signal). Intact and MMP12 treated LB206 bind to PD-L1 to a similar level. Binding to PD-L1 appears lower than atezolizumab, consistent with one-arm LB protein structure and to two-arm IgG atezolizumab.
  • FIG. 7B depicts ELISA binding of intact or 5 min MMP12 incubated LB206 protein to human CD3 ⁇ heterodimer or IgGl isotype as negative control (no signal).
  • Intact LB206 binds to human CD3 ⁇ heterodimer to very low level.
  • MMP12 treated LB206 binds strongly binds human CD3 ⁇ heterodimer.
  • FIG. 7C depicts ELISA binding of intact or 5min, 15min, 30min or 60min MMP12 incubated LB218 protein to human PD-L1 with IgGl isotype as negative control (no signal).
  • Intact and 5 or 15min MMP12 treated LB218 bind to PD-L1 to a similar level.
  • FIG. 7D depicts ELISA binding of intact or 5 min, 15min, 30min or 60min MMP12 incubated LB218 protein to human CD3 ⁇ heterodimer with IgGl isotype as negative control (no signal).
  • Intact LB218 shows binding to human CD3 ⁇ heterodimer to very low level. With increasing MMP12 treatment times, higher binding to human CD3 ⁇ heterodimer can be observed. 60min MMP12 treated LB218 shows highest binding to human CD3 ⁇ heterodimer.
  • FIG. 7E depicts ELISA binding of intact or 5min, 15min, 30min or 60min MMP12 incubated LB218 protein to cyno CD3 ⁇ heterodimer with IgGl isotype as negative control (no signal).
  • Intact LB218 shows binding to cyno CD3 ⁇ heterodimer to very low level. With increasing MMP12 treatment times, higher binding to cyno CD3 ⁇ heterodimer can be observed.
  • 60min MMP12 treated LB218 shows highest binding to cyno CD3 ⁇ heterodimer.
  • FIG. 7F depicts ELISA binding of intact or 5min, 15min, 30min or 60min MMP12 incubated LB213 protein to human PD-L1 with IgGl isotype as negative control (no signal). Intact and 5 or 15min MMP12 treated LB213 bind to PD-L1 to a similar level. While binding to PD-L1 appears lower for 30min and 60min, suggesting occurrence of protein cleavage 2 (FIG 1A).
  • FIG. 7G depicts ELISA binding of intact or 5min, 15min, 30min or 60min MMP12 incubated LB213 protein to human CD3 ⁇ heterodimer with IgGl isotype as negative control (no signal).
  • Intact LB213 shows binding to human CD3 ⁇ heterodimer to very low level. With increasing MMP12 treatment times, higher binding to human CD3 ⁇ heterodimer can be observed. 60min MMP12 treated LB213 shows highest binding to human CD3 ⁇ heterodimer.
  • FIG. 7H depicts ELISA binding of intact or 5 min, 15min, 30min or 60min MMP12 incubated LB213 protein to cyno CD3 ⁇ heterodimer with IgGl isotype as negative control (no signal). Intact LB213 shows binding to cyno CD3 ⁇ heterodimer to very low level. With increasing MMP12 treatment times, higher binding to cyno CD3 ⁇ heterodimer can be observed. 60min MMP12 treated LB213 shows highest binding to cyno CD3 ⁇ heterodimer.
  • LB protein functionality was assessed for their ability to induce tumor cell killing by primary T cells.
  • Three representative cancer cell lines based on their PD-L1 expression levels were selected as target cells.
  • PD-L1+ low (A549) cells were seeded into 96-well plates and grown for approximately 24h before addition of primary T cells (E:T 5:1) of two different donors and intact or digested LB proteins (LB206 or LB226) at concentrations ranging from O.OlnM to lO ⁇ M as indicated. Cancer cell killing was assessed using Incucyte® Live- Cell Analysis system by measuring total annexin V area over time and results are shown in FIG. 9A. Intact LB206 induced only low-level background cell killing at lO ⁇ M, while strong Annexin V signal was detected for both lO ⁇ M and I ⁇ M of digested LB206 protein.
  • O.l ⁇ M of cleaved LB206 showed very low signals, similar to lO ⁇ M intact LB206 suggesting an apparent 100-fold lower ability to direct T cell killing of undigested LB206.
  • intact LB218 did not induce A549 cancer cell killing at lO ⁇ M (FIG. 9B).
  • strong Annexin V signals over background were detected at lO ⁇ M and I ⁇ M digested LB218 samples.
  • overall induction of cell killing was lower than observed for LB206, confirming that the lower-affinity CD3 variable domains found in LB218 are less potent than those in LB206 in a primary T cell setting.
  • LB proteins were assessed for their ability to induce tumor cell killing by primary T cells in PD-L1+ high RKO cells.
  • cancer cells were seeded for approximately 24h before addition of primary T cells from two different donors and selected intact or digested LB proteins at concentrations ranging from O.Ol ⁇ M to lO ⁇ M or as indicated. Representative results are depicted in FIG. 9C.
  • Cancer cell killing was assessed using Incucyte® Live-Cell Analysis system by measuring total annexin V area over time.
  • digested LB206 induced strong and sustained cell killing even at 0. I ⁇ M in RKO cells while no or low background was observed for intact LB206 protein at I ⁇ M.
  • LB proteins for their ability to induce tumor cell killing by primary T cells in another PD-L1+ high cell line, TNBC MDA-MB-231 cells.
  • tumor cells were seeded and grown for 24h before addition of primary T cells and selected intact or digested (indicated times) LB proteins at concentrations ranging from O.Ol ⁇ M to lO ⁇ M.
  • Cancer cell killing was assessed using Incucyte® Live- Cell Analysis system by measuring total annexin V area over time. Digested LB206 and LB213 induced strong tumor cell killing of MDA-MB-231 cells over time (FIG. 9E - FIG. 9F).
  • LB206 showed most potent tumor cell killing at 10-fold lower concentrations compared to LB213 over time suggesting activation after prolonged exposure to MDA-MB-231 cells.
  • TNBC Triple Negative Breast Cancer
  • mice were subcutaneously inoculated into myeloid cytokine boosted (hGM-CSF + hIL3 + hIL4 + FLT3L) CD34+ NCG mice.
  • hGM-CSF + hIL3 + hIL4 + FLT3L myeloid cytokine boosted mice.
  • mice were intraperitoneally treated 8xQ3D with either 4.5 mg/kg, 8.5mg/kg or 12mg/kg LB proteins, IgG isotype control or atezolizumab as indicated.
  • Tumor volumes were monitored every 3 to 4 days by caliper measurements, mean tumor volumes are shown in FIG 10.
  • LB206 induced tumor regressions FIG.
  • Embodiment 1 A protein comprising a first polypeptide chain comprising a heavy chain and a second polypeptide chain comprising a light chain, wherein the heavy chain comprises, in N-terminus to C-terminus order, an anti-PD-Ll heavy chain variable (VH) domain, a first CHI domain, a first linker, an anti-CD3 VH domain, and a second CHI domain; and wherein the light chain comprises, in N-terminus to C-terminus order, an anti-PD-Ll light chain variable (VL) domain, a first immunoglobulin light chain constant region, a second linker, an anti-CD3 VL domain, and a second immunoglobulin light chain constant region.
  • VH anti-PD-Ll heavy chain variable
  • VL light chain variable
  • Embodiment 2 A protein comprising a first polypeptide chain comprising a heavy chain and a second polypeptide chain comprising a light chain, wherein the heavy chain comprises, in N-terminus to C-terminus order, an anti-PD-Ll heavy chain variable (VH) domain, a first CHI domain, a first linker, an anti-CD3 light chain variable (VL) domain, and a first immunoglobulin light chain constant region, and wherein the light chain comprises, in N-terminus to C-terminus order, anti-PD-Ll VL domain, a second immunoglobulin light chain constant region, a second linker, an anti- CD3 VH domain, and a second CHI domain.
  • VH anti-PD-Ll heavy chain variable
  • CHI first CHI domain
  • VL anti-CD3 light chain variable
  • VL immunoglobulin light chain constant region
  • the light chain comprises, in N-terminus to C-terminus order, anti-PD-Ll VL domain, a second immuno
  • Embodiment 3 The protein of embodiment 1 or 2, wherein the heavy chain comprises in N-terminus to C-terminus order, the anti-PD-Ll VH domain, the first CHI domain, the first linker, the anti-CD3 VH domain, the second CHI domain, a hinge, a CH2 domain, and a CH3 domain.
  • Embodiment 4 The protein of any one of embodiments 1-3, wherein the protein further comprises a third polypeptide chain comprising a hinge, a CH2 domain, and a CH3 domain.
  • Embodiment 5 The protein of embodiment 4, wherein the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 124.
  • Embodiment 6 The protein of embodiment 1, wherein the protein further comprises a moiety that provides half-life extension.
  • Embodiment 7 The protein of embodiment 6, wherein the moiety that provides half-life extension is polyethylene glycol (PEG) or an albumin binding domain.
  • PEG polyethylene glycol
  • Embodiment 8 A protein comprising a first polypeptide chain comprising a heavy chain and a second polypeptide chain comprising a light chain, wherein the heavy chain comprises, in N-terminus to C-terminus order, an anti-PD-Ll heavy chain variable (VH) domain, a first CHI domain, a first linker, an anti-CD3 VH domain, a second CHI domain, a first hinge, a first CH2 domain, and a first CH3 domain; and wherein the light chain comprises, in N-terminus to C-terminus order, an anti-PD-Ll light chain variable (VL) domain, a first immunoglobulin light chain constant region, a second linker, an anti-CD3 VL domain, a second immunoglobulin light chain constant region, a second hinge, a second CH2 domain, and a second CH3 domain.
  • VH anti-PD-Ll heavy chain variable
  • Embodiment 9 The protein of any one of embodiments 1-8, wherein the first linker comprises the amino acid sequence of any one of SEQ ID NOs: 1-12.
  • Embodiment 10 The protein of any one of embodiments 1-9, wherein the second linker comprises the amino acid sequence of any one of SEQ ID NOs: 1-12.
  • Embodiment 11 The protein of any one of embodiments 1-10, wherein the anti-PD-Ll VH domain comprises a HCDR1 comprising the amino acid sequence of SEQ ID NO: 20, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 21, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 22; and wherein the anti-PD-Ll VL domain comprises a LCDR1 comprising the amino acid sequence of SEQ ID NO: 23, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 24, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 25.
  • Embodiment 12 Embodiment 12.
  • the anti-CD3 VH domain comprises a HCDR1 comprising the amino acid sequence of SEQ ID NO: 26, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 27, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 29; and wherein the anti-CD3 VL domain comprises a LCDR1 comprising the amino acid sequence of SEQ ID NO: 30, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 31, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 32.
  • the anti-CD3 VH domain comprises a HCDR1 comprising the amino acid sequence of SEQ ID NO: 26, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 28, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 29; and wherein the anti-CD3 VL domain comprises a LCDR1 comprising the amino acid sequence of SEQ ID NO: 30, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 31, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 32.
  • the anti-PD-Ll VH domain comprises a HCDR1 comprising the amino acid sequence of SEQ ID NO: 20, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 21, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 22; wherein the anti-PD-Ll VL domain comprises a LCDR1 comprising the amino acid sequence of SEQ ID NO: 23, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 24, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 25; wherein the anti-CD3 VH domain comprises a HCDR1 comprising the amino acid sequence of SEQ ID NO: 26, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 27, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 29; and wherein the anti-CD3 VL domain comprises a LCDR1 comprising the amino acid sequence of SEQ ID NO: 30, a LCD
  • Embodiment 15 The protein of any one of embodiments 1-10, wherein the anti-PD-Ll VH domain comprises a HCDR1 comprising the amino acid sequence of SEQ ID NO: 20, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 21, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 22;
  • the anti-PD-Ll VL domain comprises aLCDRl comprising the amino acid sequence of SEQ ID NO: 23, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 24, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 25; wherein the anti-CD3 VH domain comprises a HCDR1 comprising the amino acid sequence of SEQ ID NO: 26, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 28, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 29; and wherein the anti-CD3 VL domain comprises a LCDR1 comprising the amino acid sequence of SEQ ID NO: 30, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 31, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 32.
  • Embodiment 16 The protein of any one of embodiments 1-15, wherein the anti-PD-Ll VH domain comprises the amino acid sequence of any one of SEQ ID NOs: 33 and 54-107.
  • Embodiment 17 The protein of any one of embodiments 1-16, wherein the anti-PD-Ll VL domain comprises the amino acid sequence of SEQ ID NO: 34.
  • Embodiment 18 The protein of any one of embodiments 1-17, wherein the anti-PD-Ll VH domain comprises the amino acid sequence of any one of SEQ ID NOs: 33 and 54-107, and the anti-PD-Ll VL domain comprises the amino acid sequence of SEQ ID NO: 34.
  • Embodiment 19 The protein of any one of embodiments 1-17, wherein the anti-CD3 VH domain comprises the amino acid sequence of any one of SEQ ID NOs: 44-48.
  • Embodiment 20 The protein of any one of embodiments 1-19, wherein the anti-CD3 VL domain comprises the amino acid sequence of any one of SEQ ID NOs: 37-42.
  • Embodiment 21 The protein of any one of embodiments 1-20, wherein the heavy chain comprises the amino acid sequence of any one of SEQ ID NOs: 116-123, 129-132, 137-141, 142, 144, 146, 147, 148, 150, and 152.
  • Embodiment 22 The protein of any one of embodiments 1-21, wherein the light chain comprises the amino acid sequence of any one of SEQ ID NOs: 53, 108- 115, 125-128, 133-136, 143, 145, 151, and 153.
  • Embodiment 23 The protein of embodiment 4, wherein:
  • the heavy chain comprises the amino acid sequence of SEQ ID NO: 122
  • the light chain comprises the amino acid sequence of SEQ ID NO: 114
  • the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 124
  • the heavy chain comprises the amino acid sequence of SEQ ID NO: 123
  • the light chain comprises the amino acid sequence of SEQ ID NO: 115
  • the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 124;
  • the heavy chain comprises the amino acid sequence of SEQ ID NO: 116
  • the light chain comprises the amino acid sequence of SEQ ID NO: 108
  • the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 124;
  • the heavy chain comprises the amino acid sequence of SEQ ID NO: 117
  • the light chain comprises the amino acid sequence of SEQ ID NO: 109
  • the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 124;
  • the heavy chain comprises the amino acid sequence of SEQ ID NO: 118
  • the light chain comprises the amino acid sequence of SEQ ID NO: 108
  • the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 124;
  • the heavy chain comprises the amino acid sequence of SEQ ID NO: 119
  • the light chain comprises the amino acid sequence of SEQ ID NO: 109
  • the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 124;
  • the heavy chain comprises the amino acid sequence of SEQ ID NO: 120
  • the light chain comprises the amino acid sequence of SEQ ID NO: 108
  • the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 124;
  • the heavy chain comprises the amino acid sequence of SEQ ID NO: 116
  • the light chain comprises the amino acid sequence of SEQ ID NO: 110
  • the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 124;
  • the heavy chain comprises the amino acid sequence of SEQ ID NO: 118
  • the light chain comprises the amino acid sequence of SEQ ID NO: 110
  • the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 124;
  • the heavy chain comprises the amino acid sequence of SEQ ID NO: 120
  • the light chain comprises the amino acid sequence of SEQ ID NO: 110
  • the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 124;
  • the heavy chain comprises the amino acid sequence of SEQ ID NO: 116
  • the light chain comprises the amino acid sequence of SEQ ID NO: 111
  • the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 124;
  • the heavy chain comprises the amino acid sequence of SEQ ID NO: 118, the light chain comprises the amino acid sequence of SEQ ID NO: 111, and the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 124;
  • the heavy chain comprises the amino acid sequence of SEQ ID NO: 120, the light chain comprises the amino acid sequence of SEQ ID NO: 111, and the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 124;
  • the heavy chain comprises the amino acid sequence of SEQ ID NO: 116
  • the light chain comprises the amino acid sequence of SEQ ID NO: 112
  • the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 124;
  • the heavy chain comprises the amino acid sequence of SEQ ID NO: 116
  • the light chain comprises the amino acid sequence of SEQ ID NO: 113
  • the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 124;
  • the heavy chain comprises the amino acid sequence of SEQ ID NO: 121
  • the light chain comprises the amino acid sequence of SEQ ID NO: 108
  • the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 124;
  • the heavy chain comprises the amino acid sequence of SEQ ID NO: 131
  • the light chain comprises the amino acid sequence of SEQ ID NO: 127
  • the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 124;
  • the heavy chain comprises the amino acid sequence of SEQ ID NO: 120
  • the light chain comprises the amino acid sequence of SEQ ID NO: 127
  • the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 124.
  • Embodiment 24 The protein of any one of embodiments 2-23, wherein the heavy chain comprises an IgG, IgE, IgM, IgD, IgA, or IgY constant region.
  • Embodiment 25 The protein of any one of embodiments 2-23, wherein the heavy chain comprises an IgGl, IgG2, IgG3, IgG4, IgAl or IgA2 constant region.
  • Embodiment 26 The protein of any one of embodiments 2-23, wherein the heavy chain comprises an immunologically inert constant region.
  • Embodiment 27 The protein of any one of embodiments 2-23, wherein the heavy chain comprises a wild-type human IgGl constant region, a human IgGl constant region comprising the amino acid substitutions L234A, L235A and G237A, a wild-type human IgG2 constant region, a wild-type human IgG4 constant region, or a human IgG4 constant region comprising the amino acid substitution S228P, wherein numbering is according to the EU index as in Kabat.
  • Embodiment 28 An immunoconjugate comprising the protein of any one of embodiments 1-27, linked to a therapeutic agent.
  • Embodiment 29 The immunoconjugate of embodiment 28, wherein the therapeutic agent is a cytotoxin, a radioisotope, a chemotherapeutic agent, an immunomodulatory agent, a cytostatic enzyme, a cytolytic enzyme, a therapeutic nucleic acid, an anti-angiogenic agent, an anti-proliferative agent, or a pro-apoptotic agent.
  • the therapeutic agent is a cytotoxin, a radioisotope, a chemotherapeutic agent, an immunomodulatory agent, a cytostatic enzyme, a cytolytic enzyme, a therapeutic nucleic acid, an anti-angiogenic agent, an anti-proliferative agent, or a pro-apoptotic agent.
  • Embodiment 30 A pharmaceutical composition comprising the protein of any one of embodiments 1-27 or the immunoconjugate of embodiment 28 or 29, and a pharmaceutically acceptable carrier.
  • Embodiment 31 A nucleic acid molecule encoding
  • Embodiment 32 An expression vector comprising the nucleic acid molecule of embodiment 31.
  • Embodiment 33 A recombinant host cell comprising the nucleic acid molecule of embodiment 31 or the expression vector of embodiment 32.
  • Embodiment 34 A method of producing a protein, the method comprising: culturing the recombinant host cell of embodiment 33 under conditions whereby the nucleic acid molecule is expressed, thereby producing the protein; and isolating the protein from the host cell or culture.
  • Embodiment 35 A method for enhancing an anti-cancer immune response in a subject, the method comprising administering to the subject a therapeutically effective amount of the protein of any one of embodiments 1-27, the immunoconjugate of embodiment 28 or 29, or the pharmaceutical composition of embodiment 30.
  • Embodiment 36 A method for treating cancer in a subject, the method comprising administering to the subject a therapeutically effective amount of the protein of any one of embodiments 1-27, the immunoconjugate of embodiment 28 or 29, or the pharmaceutical composition of embodiment 30.
  • Embodiment 37 A method for ameliorating a symptom of cancer in a subject, the method comprising administering to the subject a therapeutically effective amount of the protein of any one of embodiments 1-27, the immunoconjugate of embodiment 28 or 29, or the pharmaceutical composition of embodiment 30.
  • Embodiment 38 Embodiment 38.
  • the cancer is gastrointestinal stromal cancer (GIST), pancreatic cancer, skin cancer, melanoma, breast cancer, lung cancer, bronchial cancer, colorectal cancer, prostate cancer, stomach cancer, ovarian cancer, urinary bladder cancer, brain cancer, central nervous system cancer, peripheral nervous system cancer, esophageal cancer, cervical cancer, uterine cancer, endometrial cancer, cancer of the oral cavity or pharynx, liver cancer, kidney cancer, renal cell carcinoma, testicular cancer, biliary tract cancer, small bowel cancer, appendix cancer, salivary gland cancer, thyroid cancer, adrenal gland cancer, osteosarcoma, chondrosarcoma, or cancer of hematological tissues.
  • GIST gastrointestinal stromal cancer
  • pancreatic cancer skin cancer, melanoma, breast cancer, lung cancer, bronchial cancer, colorectal cancer, prostate cancer, stomach cancer, ovarian cancer, urinary bladder cancer, brain cancer, central nervous system cancer, peripheral nervous system cancer, esophageal cancer
  • Embodiment 39 A protein of any one of embodiments 1-27, the immunoconjugate of embodiment 28 or 29, or the pharmaceutical composition of embodiment 30, for use in enhancing an anti-cancer immune response in a subject.
  • Embodiment 40 A protein of any one of embodiments 1-27, the immunoconjugate of embodiment 28 or 29, or the pharmaceutical composition of embodiment 30, for use in treating cancer in a subject.
  • Embodiment 41 A protein of any one of embodiments 1-27, the immunoconjugate of embodiment 28 or 29, or the pharmaceutical composition of embodiment 30, for use in ameliorating a symptom of cancer in a subject.
  • Embodiment 42 A protein, an immunoconjugate, or a pharmaceutical composition for use according to any one of embodiments 39-42, wherein the cancer is gastrointestinal stromal cancer (GIST), pancreatic cancer, skin cancer, melanoma, breast cancer, lung cancer, bronchial cancer, colorectal cancer, prostate cancer, stomach cancer, ovarian cancer, urinary bladder cancer, brain cancer, central nervous system cancer, peripheral nervous system cancer, esophageal cancer, cervical cancer, uterine cancer, endometrial cancer, cancer of the oral cavity or pharynx, liver cancer, kidney cancer, renal cell carcinoma, testicular cancer, biliary tract cancer, small bowel cancer, appendix cancer, salivary gland cancer, thyroid cancer, adrenal gland cancer, osteosarcoma, chondrosarcoma, or cancer of hematological tissues.
  • GIST gastrointestinal stromal cancer
  • pancreatic cancer skin cancer, melanoma, breast cancer, lung cancer, bronchial cancer, colorectal cancer, prostate cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PCT/EP2023/058418 2022-03-30 2023-03-30 Activatable bispecific anti-cd3 and anti-pd-l1 proteins and uses thereof Ceased WO2023187130A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
JP2024557583A JP2025511002A (ja) 2022-03-30 2023-03-30 活性化可能な二重特異性抗ｃｄ３および抗ｐｄ－ｌ１タンパク質ならびにその使用
IL315768A IL315768A (en) 2022-03-30 2023-03-30 Bispecific anti-CD3 and anti-PD-L1 activatable proteins and their uses
CA3246893A CA3246893A1 (en) 2022-03-30 2023-03-30 Activable Bispecific Anti-CD3 and Anti-PD-L1 Proteins and Their Uses
AU2023246985A AU2023246985A1 (en) 2022-03-30 2023-03-30 Activatable bispecific anti-cd3 and anti-pd-l1 proteins and uses thereof
EP23717433.9A EP4499232A1 (en) 2022-03-30 2023-03-30 Activatable bispecific anti-cd3 and anti-pd-l1 proteins and uses thereof
KR1020247035680A KR20240163741A (ko) 2022-03-30 2023-03-30 활성화가능한 이중특이적 항-cd3 및 항-pd-l1 단백질 및 그의 용도
CN202380038600.4A CN119677780A (zh) 2022-03-30 2023-03-30 可活化双特异性抗cd3和抗pd-l1蛋白质及其用途
US18/889,571 US20250109206A1 (en) 2022-03-30 2024-09-19 Activatable bispecific anti-cd3 and anti-pd-l1 proteins and uses thereof
MX2024011776A MX2024011776A (es) 2022-03-30 2024-09-25 Proteínas anti-cd3 y anti-pd-l1 biespecíficas activables y usos de las mismas

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263325437P 2022-03-30 2022-03-30
US63/325,437 2022-03-30

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US18/889,571 Continuation US20250109206A1 (en) 2022-03-30 2024-09-19 Activatable bispecific anti-cd3 and anti-pd-l1 proteins and uses thereof

Publications (1)

Publication Number Publication Date
WO2023187130A1 true WO2023187130A1 (en) 2023-10-05

Family

ID=86052101

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2023/058418 Ceased WO2023187130A1 (en) 2022-03-30 2023-03-30 Activatable bispecific anti-cd3 and anti-pd-l1 proteins and uses thereof

Country Status (10)

Country Link
US (1) US20250109206A1 (https=)
EP (1) EP4499232A1 (https=)
JP (1) JP2025511002A (https=)
KR (1) KR20240163741A (https=)
CN (1) CN119677780A (https=)
AU (1) AU2023246985A1 (https=)
CA (1) CA3246893A1 (https=)
IL (1) IL315768A (https=)
MX (1) MX2024011776A (https=)
WO (1) WO2023187130A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025124266A1 (zh) * 2023-12-11 2025-06-19 合肥天港免疫药物有限公司 双特异性抗体及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7943743B2 (en) 2005-07-01 2011-05-17 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
WO2014167022A1 (en) 2013-04-09 2014-10-16 Engmab Ag BISPECIFIC ANTIBODIES AGAINST CD3EPSILON and ROR1
CN110590955A (zh) * 2018-09-17 2019-12-20 北京盛诺基医药科技股份有限公司 一种双特异性抗体
WO2020229553A1 (en) * 2019-05-13 2020-11-19 UltraHuman Six Limited Activatable bispecific antibodies comprising a linker between the two binding domains which is a human immunoglobulin hinge region, or a variant thereof, and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7943743B2 (en) 2005-07-01 2011-05-17 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
WO2014167022A1 (en) 2013-04-09 2014-10-16 Engmab Ag BISPECIFIC ANTIBODIES AGAINST CD3EPSILON and ROR1
CN110590955A (zh) * 2018-09-17 2019-12-20 北京盛诺基医药科技股份有限公司 一种双特异性抗体
WO2020229553A1 (en) * 2019-05-13 2020-11-19 UltraHuman Six Limited Activatable bispecific antibodies comprising a linker between the two binding domains which is a human immunoglobulin hinge region, or a variant thereof, and uses thereof

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
BAGSHAWE K.D. ET AL., ANTIBODY, IMMUNOCONJUGATES AND RADIOPHARMACEUTICALS, vol. 4, 1991, pages 915 - 922
CENTESSA: "Centessa", 21 April 2021 (2021-04-21), pages 1 - 399, XP093063200, Retrieved from the Internet <URL:https://www.sec.gov/Archives/edgar/data/1847903/000119312521123969/d123754ds1.htm> [retrieved on 20230712] *
DAVIES ET AL., ANNUAL REV BIOCHEM, vol. 59, 1990, pages 439 - 473
DEL BANO ET AL., FRONT. IMMUNOL., vol. 10, 2019, pages 1593
HENIKOFFHENIKOFF, PNAS, vol. 89, 1992, pages 10915 - 10919
KEMPER ET AL., LIFE SCI ALLIANCE, vol. 5, no. 11, 2022, pages e202201481
LEDERMANN J.A. ET AL., INT. J. CANCER, vol. 47, 1991, pages 659 - 664
LIU DINGKANG ET AL: "Microenvironment-responsive anti-PD-L1 x CD3 bispecific T-cell engager for solid tumor immunotherapy", JOURNAL OF CONTROLLED RELEASE, vol. 354, 1 February 2023 (2023-02-01), AMSTERDAM, NL, pages 606 - 614, XP093063209, ISSN: 0168-3659, DOI: 10.1016/j.jconrel.2023.01.041 *
LIU ET AL., J IMMUNOTHERAPY OF CANCER, vol. 9, 2021, pages e003468
MALMQVIST, NATURE, vol. 361, 1993, pages 186 - 187
SIEVERS ET AL.: "Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega", MOLECULAR SYSTEMS BIOLOGY, vol. 7, 11 October 2011 (2011-10-11), pages 539
WARD ET AL., THERAP. IMMUNOL., vol. 2, 1995, pages 77 - 94

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025124266A1 (zh) * 2023-12-11 2025-06-19 合肥天港免疫药物有限公司 双特异性抗体及其应用

Also Published As

Publication number Publication date
EP4499232A1 (en) 2025-02-05
AU2023246985A1 (en) 2024-10-03
CA3246893A1 (en) 2023-10-05
KR20240163741A (ko) 2024-11-19
US20250109206A1 (en) 2025-04-03
JP2025511002A (ja) 2025-04-15
CN119677780A (zh) 2025-03-21
IL315768A (en) 2024-11-01
MX2024011776A (es) 2025-01-09

Similar Documents

Publication Publication Date Title
US20230272100A1 (en) Antibodies against ox-40 and uses thereof
US20240018252A1 (en) Therapeutic antibodies and their uses
US20230218776A1 (en) Anti-ntb-a antibodies and related compositions and methods
CA2893977C (en) Anti-ntb-a antibodies and related compositions and methods
US20250109206A1 (en) Activatable bispecific anti-cd3 and anti-pd-l1 proteins and uses thereof
WO2023086835A1 (en) Anti-vista antibodies and uses thereof
US20250002585A1 (en) Activatable bispecific anti-cd47 and anti-pd-l1 proteins and uses thereof
EP4698563A1 (en) Activatable bispecific anti-cd89 and anti-pd-l1 proteins and uses thereof
WO2024218509A1 (en) Activatable bispecific anti-cd28 and anti pd-l1 proteins and uses thereof
CN118786144A (zh) 可活化双特异性抗cd47和抗pd-l1蛋白质及其用途
HK1246308B (en) Antibodies against ox40 and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23717433

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 315768

Country of ref document: IL

Ref document number: 814718

Country of ref document: NZ

Ref document number: AU2023246985

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: MX/A/2024/011776

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2024557583

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2023246985

Country of ref document: AU

Date of ref document: 20230330

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112024020107

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 202417077054

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 20247035680

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2023717433

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2023717433

Country of ref document: EP

Effective date: 20241030

WWE Wipo information: entry into national phase

Ref document number: 202380038600.4

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 112024020107

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20240927

WWP Wipo information: published in national office

Ref document number: 202380038600.4

Country of ref document: CN